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REGULATION AND MECHANISTIC FUNCTIONS OF CASPASE-9 RNA SPLICING
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Caspase-9 has two splice variants, pro-apoptotic caspase-9a and anti-apoptotic caspase-9b,
and dysregulation of caspase-9 splice variant ratio or expression of caspase-9b isoform has been
linked to augmentation of the anchorage-independent growth and tumorigenic capacity of nonsmall cell lung cancer (NSCLC) cells. This study focuses on cell signaling pathway(s) regulating
the alternative splicing of caspase-9 pre-mRNA and mechanistic roles of caspase-9b in a certain
oncogenic/survival pathway. In regards to the former, we have identified hnRNP U as a novel
splice-enhancer associated with exon 3 of caspase-9 (C9/E3). Moreover, hnRNP U binds

specifically to C9/E3 at an RNA cis-element previously reported as the binding site for the
splicing repressor, hnRNP L. Phosphorylated hnRNP L interferes with hnRNP U for binding to
C9/E3, and our results demonstrate the importance of the phosphoinositide 3-kinase/AKT
pathway in modulating the association of hnRNP U to C9/E3. Overall, a mechanistic model has
been revealed where hnRNP U competes with hnRNP L for C9/E3 binding to enhance the
inclusion of the four-exon cassette, and this splice-enhancing effect is blocked by the AKT
pathway via phosphorylation of hnRNP L. As to the latter aim, it is unknown about the
mechanistic roles of caspase-9b besides the inhibitory effect on caspase-9a processing. In this
study, caspase-9b has been demonstrated to have a dual function in regulating the
survival/oncogenic nuclear factor κB (NF-κB) pathway, which is independent from modulating
caspase-9a activation. In particular, caspase-9b has been shown to activate the canonical arm and
inhibit the non-canonical arm of the NF-κB pathway by destabilizing NF-κB inhibitor alpha
(IκB-α) and NF-κB-inducing kinase (NIK). Importantly, this new role for caspase-9b contributes
to the enhanced survival and anchorage-independent growth of NSCLC cells conferred by
caspase-9b expression. Further mechanistic studies have demonstrated a direct association of
caspase-9b with the cellular inhibitor of apoptosis 1 (cIAP1), a regulatory factor in both arms of
the NF-κB network, via its IAP-binding motif. Through this interaction, caspase-9b induces the
E3 ligase activity of cIAP1, which regulates NF-κB activation, and promotes the survival,
anchorage-independent growth and tumorigenicity of NSCLC cells. Overall, a novel tumorigenic
mechanism has been identified, by which alternative mRNA processing regulates the NF-κB
signaling independent of external agonist.

CHAPTER 1 – INTRODUCTION:
REGULATION OF CASPASE-9 SPLICING BY HNRNP U

1.1 Non-small cell lung cancer
Lung cancer is the leading cause of cancer-related death in both men and women worldwide
and accounts for an estimated 28% of all cancer deaths in the United States (50). Death rates
from lung cancer have not been changed considerably over the past 50 years despite the
advances in cancer treatment and improvements in lifestyle and health care. Non-small cell lung
cancer (NSCLC) represents the majority of lung cancers with poor prognosis and a cumulative
five-year survival rate of less than 18% (70). Most patients present with unresectable disease and
therefore, chemotherapy and/or radiation are the current treatment options. However, the
treatment efficacy is restricted by the rapid development of chemo- or radio-resistance (13).
Thus, development of new therapy approaches, especially new therapeutic targets, is necessary
to reduce the mortality from this disease.
1.2 Apoptosis: the intrinsic and extrinsic pathway
Apoptosis is a distinctive mode of “programmed cell death”, which plays critical roles in
regulation of tissue homeostasis (18). Apoptosis process is often energy-dependent, irreversible
and highly coordinated by a cascade of molecular events. The most important factor mediating
apoptosis is a group of cysteine proteases called caspases, which are capable of cleaving
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specific proteins in the cytoplasm and nucleus to trigger cell death. Caspases exist in the cells as
inactive precursors, or procaspases, which are usually activated by other caspases, resulting in a
proteolytic caspase cascade. Caspase activation is regulated by members of the Bcl-2 family and
the inhibitor of apoptosis (IAP) proteins.
Two main apoptotic pathways have been identified: the extrinsic or death receptor pathway
and the intrinsic or mitochondrial pathway (figure 1.1). Although these two pathways differ in
the initiation phase, they both end at the point of the execution phase including caspase-3
activation, DNA fragmentation, degradation of cytoskeletal and nuclear proteins, protein
crosslinking, formation of apoptotic bodies, expression of ligands for phagocytic cell receptors
and uptake of apoptotic bodies by phagocytic cells. For the initiation phase in the extrinsic
pathway, engagement of death receptors results in the formation of the death-inducing signaling
complex (DISC) containing the death receptors, adaptor proteins, caspase-8 and caspase-10
whereas the intrinsic pathway is initiated by the release of cytochrome c from the mitochondria
into the cytosol to trigger the formation of apoptosome containing cytochrome c, apaf-1 and
caspase-9. Further recruitment of caspases to DISC and apoptosome leads to their activation by
dimer formation.
Various key factors in apoptosis have been identified; however, the molecular mechanisms of
many of these remain inclusive. Since dysregulation of apoptosis, either increased or inadequate
apoptosis, is implicated in many disease states, including neurodegenerative disorder, acquired
immune deficiency syndrome (AIDS), ischemic damage, autoimmune disorders and many types
of cancer, further studies regarding the mechanisms of apoptosis would have significant impacts
on developing therapeutic strategy against apoptosis-related diseases.
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1.3 Caspase-9 splicing
Among the 14 caspases identified to date, caspase-9 is one of the most important initiators of
the intrinsic apoptotic pathway. For example, the activation of caspase-9 via interaction with
Apaf-1 and cytochrome c to form the apoptosome activates downstream caspases to amplify
apoptotic signaling. There are two splice variants of caspase-9, caspase-9a and caspase-9b, that
can be generated by the inclusion or exclusion of exon 3,4,5,6 cassette in the mature caspase-9
mRNA (figure 1.2). Different from caspase-9a (or procaspase-9), caspase-9b lacks the catalytic
domain, but retains the caspase recruitment/Apaf-1 association domain (CARD) (figure 1.2).
Thus, apposing to caspase-9a, which is a pro-apoptotic protein, caspase-9b functions as an
apoptotic inhibitor by competing with caspase-9a for binding to Apaf-1 and consequently
suppressing caspase-cascade activation (55, 59).
The ratio of caspase-9a/9b isoform is dysregulated in NSCLC cells (21, 57), and several
factors implicated in regulating the alternative splicing of caspase-9 include endogenous
ceramides (8), SRSF1 (SRp30a or ASF/SF2) (45, 57, 58) and heterogeneous nuclear
ribonucleoprotein L (hnRNP L) (21). De novo ceramide synthesis and SRSF1 have been
documented to down-regulate the level of caspase-9b mRNA in contrast to hnRNP L, which
represses the inclusion of four-exon cassette to favor the formation of caspase-9b. Importantly,
phosphorylation of SRSF1 or hnRNP L and subsequent effects on the caspase-9 splicing process
has been shown to be important in sensitizing non-small cell lung cancer (NSCLC) cells to
chemotherapeutics and promoting the tumorigenic capacity of these cells (21, 58). Hence,
modulation of caspase-9 splicing or caspase-9 splice variant ratio would be a promising cancerspecific approach for treatment of NSCLC.
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1.4 hnRNP U protein
hnRNP U, also known as SP120, is the largest of major heterogeneous nuclear
ribonucleoproteins (120 KDa). It is capable of binding to both DNA through the acidic region in
the N-terminal and RNA via the RGG box in the C-terminal (19, 34) (figure 1.3). hnRNP U is
also a major constituent of nuclear matrix or scaffold and is, thereby, termed scaffold attachment
factor A (SAF-A). Various biological functions of hnRNP U have been reported: regulation of
gene transcription (17, 35, 36, 53), controlling RNA stability (68), participating in X inactivation
process (23, 25) and controlling telomere length (20). The splicing regulatory function of hnRNP
U has just emerged recently (69) with hnRNP U shown to modulate SMN2 splicing via
controlling U2 snRNP maturation. The multiple biological roles of hnRNP U might explain why
mice carrying a hypomorphic mutation in the hnRNP-U gene exhibit post-implantation lethality.
1.5 Specific aims of the study
Previously in the laboratory, four RNA trans-factors were identified to associate with the
purine-rich sequences in C9/E3, including hnRNP L, hnRNP A2/B1, hnRNP R and hnRNP U
(Table 1.1), and this association suggested a possible biological function in regulating caspase-9
mRNA processing (21). The roles of hnRNP L and hnRNP A2/B1 on caspase-9 splicing were
further examined by Goehe et al in the laboratory (21). In this study, we examined the roles of
the two other factors, hnRNP U and hnRNP R, on caspase-9 RNA splicing and found the
involvement of hnRNP U in regulating caspase-9 splicing through interaction with target mRNA.
The precise binding sites for hnRNP U on caspase-9 mRNA were also determined. Additionally,
we investigated the mechanism that regulates the interaction between hnRNP U and exon 3 of
caspase-9, which determines the preferential expression of caspase-9a or caspase-9b.
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Figure 1.1 Intrinsic and extrinsic pathway in apoptosis. The intrinsic pathway is initiated
within the cells and is triggered by different signals as a result of DNA damage, severe cell stress
or loss of cell-survival factors. Activation of the intrinsic pathway normally leads to the release
of pro-apoptotic proteins from the mitochondria, the center of the intrinsic signaling, to activate
caspase cascade, including the initiator and effector caspases, and execute apoptosis. The
extrinsic pathway is initiated outside the cell via association between the pro-apoptotic ligands
and pro-apoptotic receptors on the cell surface. Ligand binding results in receptor clustering and
formation of death-inducing signaling complex (DISC). After DISC activation, the extrinsic
pathway utilizes the same effector caspase machinery as the intrinsic pathway.
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Figure 1.2 Schematic representation of caspase-9a/b mRNA and protein structure. The
alternative splicing of caspase-9, specifically the inclusion or exclusion of the four-exon cassette,
generates two different splicing products, caspase-9a and caspase-9a. Caspase-9b protein
translated from caspase-9b splice variant lacks almost the large subunit, including the catalytic
site.
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Figure 1.3 Schematic representation of hnRNP U protein structure. hnRNP U contains the
amino-terminal acidic region, which mediates its binding to DNA sequence termed scaffold
attachment region (SAR), and RGG box in the carboxy-terminal glycine-rich region, which
enables it to bind to RNA sequence. NLS and NTP denotes the putative nuclear localization
signal and NTP binding site.
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CHAPTER 2 – MATERIALS AND METHODS:
REGULATION OF CASPASE-9 SPLICING BY HNRNP U

2.1 Cell culture
A549 lung adenocarcinoma cells were cultured in DMEM medium with 10% (v/v) FBS
(Sigma-Aldrich), 100 U/ml penicillin and 100 µg/ml streptomycin sulfate (Invitrogen). Human
bronchial epithelial primary cells (HBEpC) were cultured in Bronchial/Tracheal Epithelial Cell
Growth medium (Cell Applications). All cells were maintained at less than 80% confluency
under standard incubator conditions. For the comparison studies between A549 versus HBEpC
cell lines, cells were plated in tissue culture plates (100 mm), which gave 40% confluency. The
following day, medium was changed to serum-free DMEM and cell plates were incubated
overnight before total protein or cell lysates were isolated for analysis.
2.2 Electrophoretic mobility shift assay (EMSA)
RNA-binding reaction mixtures (20 µl) containing 10 µg of A549 or HBEpC cell lysates, 40
U RNASIN, 11.3 µg tRNAs, 10 mM HEPES, 5 mM DTT, 120 mM KCl, 3 mM MgCl 2, 5%
glycerol and 10 μM of FITC tagged RNA oligos (C9/E3 WT, C9/E3 Mut1, C9/E3 Mut2, C9/E3
Mut3 or C9/E3 Mut4) were incubated on ice for 20 minutes. Then 2 µg of hnRNP U antibody or
BSA (control) was added to each binding mixture and the mixtures were incubated for additional
30 minutes. Samples were loaded on a 5% TBE-polyacrylamide gel for electrophoresis
separation. RNA-protein complexes were then visualized by using Molecular Imager FX (BioRad) with a 488 nm EX (530 nm BYPASS) laser.
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2.3 Densitometric analysis of the EMSA supershift
The fold-differences in hnRNP U-E3/C9 binding between A549 and HBEpC cells were
determined by densitometric measurement of the hnRNP U supershift in the scanned EMSA gels
from three independent experiments (n=4) using ImageJ densitometry software (NIH).
2.4 Mass spectrometry analysis
Analysis of RNA-protein complexes was performed at the Emory University Mass
Spectrometry Center (Atlanta, Georgia, USA) as previously described (21). Briefly, RNAprotein complexes retrieved from EMSA were excised from the gel following by in-gel trysin
digestion. The tryptic mixtures were then analyzed by nano– LC-MS/MS. Nano–LC-MS/MS
results were obtained by searching through Mascot database (Matrix Science).
2.5 siRNA transfection
A549 or HBEpC cells were transfected with negative control siRNA or hnRNP U
SMARTpool siRNA or hnRNP R siRNA (Dharmacon) using Dharmafect 1 transfection reagent
(Dharmacon). Cells (3-4 x 105) were plated in each well of 6-well tissue culture dishes in regular
growth medium. The following day, cells were plated in Opti-MEM I medium without
antibiotics/FBS and transfected with 100 nM of siRNA (diluted in 1X siRNA buffer). After 4
hours of incubation, 0.5 ml Opti-MEM I medium containing 3-fold the normal concentration of
antibiotics/FBS was added to the 1ml of transfection mixture. Cells in transfection mixture were
incubated for additional 4 hours before medium was changed to normal growth medium. After
48 hours, total RNA or protein was collected from the cell lysates.
2.6 Competitive RT-PCR
Total RNA was extracted from the cells using the RNeasy Mini Kit (Invitrogen) and then
reverse transcribed to cDNA using SuperScript III Reverse Transcriptase Kit (Invitrogen). The

9

reverse transcription reaction products were utilized in PCR for the endogenous caspase-9
primers

(sense

primer

5'-CATGCTGGCTTCGTTTCTG-3' and

anti-sense

primer

5'-

AGGGGCAAACAACAGATGG-3'). PCR was performed in 25 cycles of 94oC for 30 seconds,
58oC for 30 seconds and 72oC for 1 minute. The final PCR products were resolved on 5% TBE
polyacrylamide gel, stained with SYBR Gold (Invitrogen) and visualized by using Molecular
Imager FX (Bio-Rad) with a 488 nm EX (530 nm BYPASS) laser.
2.7 Quantitative RT-PCR
Total RNA was extracted from the cells using the RNeasy Mini Kit (Invitrogen) and then
reverse transcribed to cDNA using SuperScript III Reverse Transcriptase Kit (Invitrogen). The
reverse transcription reaction products were utilized for real-time PCR for Casp9a, Casp9b, and
18s using TaqMan PCR master mix and the Applied Biosystems 7500 Real-Time PCR System.
Casp9a and 18s q-PCR primers were ID numbers Hs00154261_m1 and Hs99999901_s1. The qPCR primers for Casp9b were 5’-GGATTTGGTGATGTCGAGCAG-3′ (forward), 5′CATCTGGCTCGGGGTTACT-3′ (reverse) and 5′-TTCCCCTGAAGACGAGTCCCCTGG-3′
(probe). The relative amount of Casp9a or Casp9b was normalized to 18s.

2.8 Cell lysate preparation
Cell lysates, except for the CIP experiments, were prepared by lysing the cells in NP-40 lysis
buffer (50 mM Tris-HCl at pH 8.0, 150 mM NaCl, 1% NP-40 and 1X protease/protein
phosphatase inhibitor cocktail). For cell lysates utilized for the CIP treatment experiments, cells
were lysed in the same NP-40 buffer as detailed above, but without protein phosphatase
inhibitors. Lysates were also utilized “fresh” for these experiments (i.e. same day), and not
stored.
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2.9 Streptavidin-biotin affinity purification (SBAP)
Reaction mixtures (20 µl) containing 10 µg of cell lysates or 4 µg of IgG (control), 40 U
RNASIN, 11.3 µg tRNAs, 10 mM HEPES, 5 mM DTT, 120 mM KCl, 3 mM MgCl 2, 5%
glycerol and 10 µM biotinylated RNA oligo (C9/E3 WT, C9/E3 Mut1, C9/E3 Mut2, C9/E3 Mut3
or C9/E3 Mut4) were incubated on ice for 30 minutes. Pre-washed streptavidin-agarose beads
were then added to the reactions following by 2 hour of incubation with gentle agitation (4°C).
After incubation, the reactions were washed 3 times with pre-block buffer (100 mM KCl, 20 mM
Tris-HCl at pH 7.5 and 0.2 mM EDTA) and centrifuged to collect the pellet. The pellet was
resuspended in Laemmli buffer, dry-boiled for 10 minutes and subjected to western
immunoblotting.
2.10 In vitro phosphatase treatment
Phosphatase reaction mixtures containing 10 μg cell lysate and 10U calf-intestinal
phosphatase (CIP) or heat-inactivated CIP (denatured CIP, control) in 1X NEBuffer 3 (New
England BioLabs) were incubated at 37oC. After 1 hour of incubation, 1X phosphatase inhibitor
cocktail was added to the mixtures. Reaction mixtures were then utilized in EMSA or SBAP for
RNA-protein binding analysis.
2.11 Immunoprecipitation (IP)
Cells were lysed in 1X IP buffer containing 1% Trition X-100, 150 mM NaCl, 10 mM Tris
pH 7.4, 1mM EDTA pH 8.0, 0.5% NP-40 and 1X phosphatase/protease inhibitor cocktail.
Sample lysates (200 μg) were pre-cleared with pre-washed protein G Sepharose beads for 1 hour
at 4oC in gentle agitating condition. After pre-clearing, samples were centrifuged and collected
from the supernatants. 4 µg of hnRNP U or hnRNP L monoclonal antibody was placed in each
sample and in 4oC for 2 hour with gentle agitation before pre-washed protein G Sepharose beads
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were added. The following day, the bead complexes were centrifuged, washed extensively with
1X IP buffer, pelleted by centrifugation, resuspended in Laemmli buffer, dry-boiled for 10
minutes and subjected to SDS-PAGE/immunoblotting. For IP experiments coupled with CIP
treatment, cells were lysed in the same IP buffer, but without protein phosphatase inhibitors. The
IPs were then subjected to CIP treatments as detailed in the above method section.
2.12 In vitro kinase assay
Kinase reaction mixtures (20 μl) containing 80 ng of recombinant hnRNP L, 10 mM
HEPES, 5 mM DTT, 120 mM KCl, 3 mM MgCl2, 5% glycerol, 0.5 mM ATP, 1.25 mM
glycerol-2-phosphate and 200 ng of AKT2 (Sigma) were incubated at 30oC for 30 minutes.
Reaction mixtures were then utilized in EMSAs for RNA-protein binding analysis or SBAPbased competitive binding assays.
2.13 Competitive binding assay
Recombinant hnRNP L was subjected to in vitro kinase assay. Kinase reaction mixtures (20
µl) were then incubated with 40 U RNASIN, 11.3 µg tRNAs, 10 mM HEPES, 5 mM DTT, 120
mM KCl, 3 mM MgCl2, 5% glycerol and 10 μM biotinylated C9/E3 ROs on ice for 30 minutes.
Pre-washed streptavidin-agarose beads were then added to the reactions following by 2 hour of
incubation with gentle agitation (4°C). After incubation, the reactions were washed 3 times with
pre-block buffer (100 mM KCl, 20 mM Tris-HCl at pH 7.5 and 0.2 mM EDTA) and centrifuged
to pellet the bead complexes. The bead complexes were then incubated with binding mixtures
(20 μl) containing 10 μg of HBEpC cell lysates, 40 U RNASIN, 11.3 µg tRNAs, 10 mM
HEPES, 5 mM DTT, 120 mM KCl, 3 mM MgCl and 5% glycerol for additional 2 hours. After
incubation, the bead complexes were washed 3 times with pre-block buffer (100 mM KCl, 20
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mM Tris-HCl at pH 7.5 and 0.2 mM EDTA), pelleted by centrifugation, resuspended in Laemmli
buffer, dry-boiled for 10 minutes and subjected to SDS-PAGE/immunoblotting.
2.14 Statistical analysis
Statistical differences in the mRNA level between the control and hnRNP U siRNA treated
cells were determined by a 2-tailed, unpaired Student’s t test. Statistical differences in the
association of hnRNP U with E3/C9 between A549 and HBEpC cells were determined by onesample t-test. P values of less than or equal to 0.05 were considered significant.
2.15 Antibody information
The following antibodies were used in western immunoblotting or EMSA/supershift: anticaspase-9 (Assay Designs), anti-hnRNP U (Sigma-Aldrich), anti-β-actin (Cell Signaling
Technology), anti-laminA/C (Cell Signaling Technology), anti-phospho-serine (Cell Signaling
Technology),

anti-phospho-threonine

(Cell

Signaling

Technology),

anti-phospho-

(serine/threonine)-AKT substrate (Cell Signaling Technology), AKT2 (Cell Signaling
Technology), anti-hnRNP L (Santa Cruz Biotechnologies Inc.), anti-phospho-Ser52-hnRNP L
(custom anti-produced via Genscript Corporation) (21), horseradish peroxidase-conjugated antirabbit IgG antibody (Cell Signaling Technology) and horseradish peroxidase-conjugated antimouse IgG antibody (Cell Signaling Technology).
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CHAPTER 3 – RESULTS:
REGULATION OF CASPASE-9 SPLICING BY HNRNP U

3.1 Identification of hnRNP U associated with exon 3 of caspase-9 and suppressing the
formation of the caspase-9b isoform
Using EMSA coupled to nanospray LC-MS/MS analysis, four RNA trans-factors, hnRNP L,
hnRNP A2/B1, hnRNP R and hnRNP U, were previously identified to associate with the purinerich sequences in C9/E3 (Table 1.1) (21). hnRNP L was then further characterized to modulate
the alternative splicing of caspase-9 pre-mRNA as a repressor of the inclusion of the exon 3,4,5,6
cassette whereas hnRNP A2/B1 did not affect caspase-9 splicing (21). Here, we examine the
roles of the two other RNA trans-factors, hnRNP U and hnRNP R, on the alternative splicing of
caspase-9 by employing siRNA technology. Whereas downregulation of hnRNP U reduced the
endogenous caspase-9a/9b mRNA ratio in both transformed A549 cells and non-transformed
human bronchial epithelial primary cells (HBEpC) (Fig. 1.4A-D), hnRNP R depletion yielded no
change in the ratio of caspase-9a/9b mRNA (Fig. 1.4A and B). Importantly, the effect of hnRNP
U on the mRNA ratio translated to the protein level (Fig. 1.4E). These data indicate that hnRNP
U inhibits the formation of caspase-9b via suppressing the exclusion of four-exon cassette in the
mature caspase-9 mRNA.
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Since the two splice variants of caspase-9, caspase-9a and caspase-9b, are generated from the
same gene and have the same 5’UTR and 3’UTR sequences, the effect of hnRNP U depletion on
caspase-9a/9b ratio is likely attributable to the regulation of the alternative splicing of caspase-9
rather than mRNA stability. Indeed, no significant difference in the decay rate (specifically,
RNA half-life t1/2) of caspase-9a or caspase-9b mRNA was observed after treatment of the
control versus hnRNP U-depleted cells with actinomycin D (Fig. 1.4F-H). These data “rule out”
the possibility that hnRNP U represses the production of caspase-9b by stabilizing caspase-9a
mRNA or destabilizing caspase-9b mRNA. Hence, regulation of the alternative splicing of
caspase-9 is most likely the mechanism contributing to the observed enhancing function of
hnRNP U in the inclusion of the four-exon cassette.
3.2 hnRNP U binds specifically to exon 3 of caspase-9 pre-mRNA
The LC-MS/MS results strongly suggested that hnRNP U interacted with C9/E3. To
determine whether hnRNP U interacts specifically with C9/E3, EMSA coupled with an hnRNP
U “supershift” was performed (Fig. 1.5A and Table 1.2 for sequences utilized). Indeed, a
“supershift” was observed after the addition of an anti-hnRNP U antibody indicating that hnRNP
U is present in the C9/E3-protein complex, and thereby, verifying the LC-MS/MS results (Fig.
1.5B). Furthermore, this “supershift” was specific for hnRNP U since reduction in levels of
hnRNP U via siRNA resulted in the loss of the supershift (Fig. 1.5C and D).
Mutagenesis analysis was employed to further determine/validate the binding site for hnRNP
U in C9/E3. As shown in Fig. 1.5E and F, the interaction between hnRNP U and C9/E3 was
completely abolished in one out of four C9/E3 mutations (Mut3). Interestingly, this interaction
site has been previously identified as the binding site for hnRNP L, a repressor that regulates the
alternative splicing of caspase-9 (21). Two additional mutations (Mut2 and Mut4) flanking this
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site also significantly diminished the association of hnRNP U to C9/E3 (Fig. 1.5E and F). These
findings reveal that hnRNP U specifically interacts with the hnRNP L binding site in C9/E3.
Also of note, almost a complete loss of protein:RNA complexes was observed with Mut3 in
accord with our previous findings of hnRNP L binding to this region. These data also suggest
that hnRNP L, hnRNP U, or both may also target additional RNA trans-factors to exon 3 of
caspase- 9.
3.3 Phosphorylation regulates the interaction between hnRNP U and exon 3 of caspase-9
pre-mRNA
Although hnRNP U was expressed at the same level in non-transformed (HBEpC) versus
transformed (A549) cells (Fig. 1.6A), the association of this RNA trans-factor to C9/E3 in
HBEpC cells was significantly higher than in A549 cells (Fig. 1.6B and C). Specifically, the
fold-difference as assayed by EMSA analysis was 1.70 ± 0.18 (mean ± SD) (p < 0.01).
Selective phosphorylation of hnRNP U has been reported in a study of Burglund and Larke
(2009) (3). Thus, we hypothesized that the enhanced binding of hnRNP U to C9/E3 in nontransformed cells compared to transformed cells was due to the differences in post-translational
modification, particularly the phosphorylation state. To address this possibility, protein
phosphatase treatments coupled with RNA binding assays were undertaken. Congruent with our
hypothesis, the dephosphorylation of NSCLC (A549) cell lysates resulted in significant
enhancement of the association of hnRNP U to C9/E3 (Fig. 1.6C-E). These findings implicate
phosphorylation as a regulatory mechanism for hnRNP U-C9/E3 interaction, which may explain
the differences observed in non-transformed versus transformed cells regarding hnRNP U-C9/E3
binding.
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To determine whether the phosphorylation of RNA trans-factors was the mitigating factor in
modulating the differential association of hnRNP U to C9/E3 in transformed cells versus nontransformed cells, both A549 and HBEpC cell lysates were subjected to phosphatase (CIP)
treatment (denatured versus active) in the absence of protein phosphatase inhibitors.
Dephosphorylation of A549 cell lysates increased the association of hnRNP U to C9/E3 to
comparable levels of the binding observed in HBEpC cell lysates, whereas the association of
hnRNP U in the non-transformed cells was unaffected (Fig. 1.6F). These data demonstrated that
the disparity in hnRNP U binding between transformed and non-transformed cells is due to the
phosphorylation state of RNA trans-factors (Fig. 1.6G).
3.4 Inhibition of the AKT pathway promotes the association of hnRNP U with C9/E3 and
alters the ratio of caspase-9 splice variants
The phosphoinositide 3-Kinase/AKT pathway has been reported to modulate the alternative
splicing of caspase-9 (57), and we hypothesized that this signaling pathway modulates the ability
of hnRNP U to bind C9/E3. Indeed, treatment the NSCLC cells with AKT1/2 inhibitor increased
the binding of hnRNP U to C9/E3 in a dose-responsive manner, but did not significantly affect
its expression level (Fig. 1.7A). Importantly, enhanced association of hnRNP U to C9/E3 by
AKT inhibitor treatment correlated with the increasing caspase-9a/9b ratio in NSCLC cells (Fig.
1.7A). In contrast, ectopic expression of constitutively active AKT2 (caAKT2) in nontransformed HBEpC cells attenuated the binding of hnRNP U to C9/E3, which correlated with a
decrease in the caspase-9a/9b ratio (Fig. 1.7B). These data demonstrate that AKT signaling
regulates the interaction of hnRNP U with caspase-9 pre-mRNA.

17

3.5 The phospho-state of hnRNP U is not affected by AKT inhibition
The culmination of our data coupled to reports in the literature of hnRNP U being selectively
phosphorylated led to the initial hypothesis that the phospho-state of hnRNP U regulates the
association of the RNA trans-factor to C9/E3 (Fig. 1.7G). In direct opposition to this hypothesis,
treatment of A549 cells with an AKT inhibitor had no significant effect on the phosphorylation
state of hnRNP U (Fig. 1.8A) and in vitro phosphatase treatment showed a minor effect on
serine-phosphorylation (Fig. 1.8B). Importantly, treatment with AKT inhibitor or phosphatase in
the same condition has been shown to affect the binding of hnRNP U to C9/E3 (figure 1.6D, E, F
and figure 1.7A), which indicates that phospho-state of hnRNP U does not play an important role
in regulating the association of the RNA trans-factor with C9/E3.
3.6 hnRNP L is phosphorylated in an AKT-dependent manner inducing competition with
hnRNP U for C9/E3 binding
Since the phospho-state of hnRNP U is not critical to hnRNP U-C9/E3 interaction, we
hypothesized that the phosphorylation of other regulatory RNA trans-factors modulated the
ability of hnRNP U to associate with C9/E3. In this regard, hnRNP U shares the same binding
site as hnRNP L, which has the opposite function in regards to regulating the alternative splicing
of caspase-9 pre-mRNA. Therefore, we examined the direct binding of recombinant hnRNP L
purified from non-transformed HEK293 cells to the C9/E3. Interestingly, direct binding of
recombinant hnRNP L to this purine-rich sequence was not observed by EMSA (Fig. 1.9A, lane
1), congruent with a report showing the interaction of this recombinant hnRNP L to be specific
for CA-repeats (51). As caspase-9 RNA splicing is regulated by the phosphorylation of hnRNP L
(21), we examined whether AKT directly phosphorylates hnRNP L and induces the association
of the RNA trans-factor with C9/E3. Intriguingly, AKT efficiently phosphorylated hnRNP L,
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which induced its binding to C9/E3 (Fig. 1.9A). Moreover, inhibition of AKT signaling in
NSCLC cells directly by AKT inhibitor treatment or indirectly by blocking EGFR activity with
erlotinib treatment significantly reduced the phospho-state of hnRNP L (Fig. 1.9B). Lastly,
hnRNP L phosphorylated by AKT interfered with hnRNP U for binding to C9/E3 (Fig. 1.9C) in
contrast to non-phosphorylated hnRNP L. Taken together, these data demonstrate that the
phospho-status of hnRNP L is regulated by AKT signaling in NSCLC, which induces the
association of this RNA trans-factor and restricts the access of the enhancing factor, hnRNP U,
to C9/E3 (Fig. 1.9D).
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Table 1.1 RNA trans-factors associated with exon 3 of caspase-9 in NSCLC cells.
RNA trans-factors
hnRNP A2/B1
hnRNP L
hnRNP R
hnRNP U
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Table 1.2 RNA oligos (ROs) utilized in the RNA binding assays (EMSA or SBAP). For mutant
C9/E3 ROs, the mutated sites are located in the underlined sequences.
RO code

Sequence

NSC

CAGAAUUCGCACGUUACU

C9/E3 WT

GAGAGUUUGAGGGGAAAU

C9/E3 Mut1

CAGAAUUUGAGGGGAAAU

C9/E3 Mut2

GAGAGCCCGAGGGGAAAU

C9/E3 Mut3

GAGAGUUUCUACUGAAAU

C9/E3 Mut4

GAGAGUUUGAGGGUUACU
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Figure 1.4 hnRNP U, but not hnRNP R, represses the formation of caspase-9b via RNA
splicing. A549 or HBEpC cells were transfected with control siRNA (100 nM), hnRNP U
SMARTpool siRNA (100 nM), or hnRNP R siRNA (100 nM) for 48 hours. (A) Total RNA was
isolated and analyzed by competitive/quantitative RT-PCR for caspase-9 splice variant ratio
using ratio-based quantitation. (B) Total protein extracts were subjected to
SDS/PAGE/immunoblotting for hnRNP U, hnRNP R or β-actin. (C) Graphs were created from
the results in (A). (D) Total RNA isolated from A549 cells transfected with control or hnRNP U
siRNA was analyzed for relative amount of caspase-9a or 9b mRNA by quantitative RT-PCR
using the standard curve method and 18s rRNA as a normalizing control. (E) Total protein
extracts were subjected to SDS/PAGE/immunoblotting for caspase-9 or β-actin. Data are shown
as means ± SD (n≥4 on at least 2 independent occasions).
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Figure 1.4 (F) A549 cells were transfected with siRNA as in (A). After 48 hours, cells were
treated with actinomycin D (5 μg/ml) for 0, 2, 4 or 8 hours. RNA was isolated and relative
amount of caspase-9a or 9b mRNA (fold change compared to the si-control or si-hnRNP U
samples at 0 hour) was individually determined by quantitative RT-PCR. (G) Half-life of
caspase-9a or caspase-9b mRNA was calculated based on the data in (F). (H) Total protein from
siRNA transfected cells (48 hours) was subjected to SDS/PAGE/immunoblotting for hnRNP U
or β-actin. Statistical significance was evaluated by Student’s t test (p < 0.0001, n = 5 on two
independent occasions).
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Figure 1.5 hnRNP U binds to exon 3 of caspase-9. (A) Schemetic illustration of caspase-9 premRNA structure. 18-mer C9/E3 RNA oligos (ROs) used in RNA binding assays are
corresponding to the purine-rich sequence in C9/E3. (B and C) EMSAs were performed in the
absence of protein phosphatase inhibitors using 5’-FITC tagged C9/E3 ROs and in the presence
of IgG (control), A549 cell lysates (B) or lysates from A549 cells transfected with control siRNA
or hnRNP U SMARTpool siRNA (C). (D) Cell lysate input in (C) was subjected to SDS-PAGE
and immunoblotted for hnRNP U and β-actin. (E) SBAP was performed using 5’-biotinylated
non-specific control (NSC), 5’-biotinylated wild-type C9/E3 ROs (C9/E3 WT) or 5’-biotinylated
mutant C9/E3 ROs (C9/E3 Mut1-4) in the presence of IgG (control) or A549 cell lysates. (F)
EMSAs were performed as in (C), but using addtitional ROs (5’-FITC tagged C9/E3 Mut1-4).
Arrows indicate the supershifts obtained by the addition of the hnRNP U antibody. The graphs
shown in (B), (C), (E) and (F) are representative of n=4 from three independent experiments.
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Figure 1.6 Phosphorylation regulates the association of hnRNP U with exon 3 of caspase-9.
(A) hnRNP U is expressed at the same level in both transformed and non-transformed cells.
A549 (transformed) and HBEpC (non-transformed) cells were cultured under the same condition
(DMEM media with/without FBS) and confluency. Total protein extracts were subjected to SDSPAGE/immunoblotting for hnRNP U and β-actin. (B and C) hnRNP U binds to C9/E3 in higher
amounts in HBEpCs than in A549 cells. SBAP assays (B) or EMSAs in the presence of protein
phosphatase inhibitors (C) were performed with either IgG (control) or lysates from A549 or
HBEpC cells using a 5’-biotinylated or 5-FITC tagged wild-type C9/E3 ROs. (D and E)
Dephosphorylation increases the binding affinity of hnRNP U to C9/E3. A549 cell lysates
(“fresh”) were pre-incubated with denatured calf-intestinal alkaline phosphatase (de-CIP) or
active protein phosphatase (CIP) followed by EMSA (D) in the absence of protein phosphatase
inhibitors or SBAP (E) to assay the binding with 5’-FITC tagged (D) or 5’-biotinylated (E)
C9/E3 ROs. IgG was used as a control. (F) Dephosphorylation abolishes the difference between
A549 versus HBEpC regarding the binding of hnRNP U to E3/C9. A549 (transformed) and
HBEpC (non-transformed) cells were cultured under the same conditions and confluency, and
cell lysates were produced. Lysates (“fresh”) were again treated and assayed as in (E). (G)
Hypothetical model for regulation of hnRNP U/L-C9/E3 interaction by phosphorylation.
Whereas the phosphorylation event augments the association between hnRNP L and C9/E3,
phosphorylation of hnRNP U attenuates its binding to C9/E3. The graphs shown in (A), (B), (C),
(D), (E) and (F) are representative of n=4 from three independent experiments.
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Figure 1.7 AKT pathway regulates the association of hnRNP U to exon 3 of caspase-9. (A)
Inhibition of AKT1/2 activity increases the caspase-9a/9b ratio and enhances the binding of
hnRNP U to C9/E3 in a dose-response manner. A549 cells were treated with 0.1% DMSO
control or increasing concentrations of the AKT1/2 inhibitor (AKT VIII). Total RNA was
isolated and analyzed for caspase-9 splice variants by competitive/quantitative RT-PCR. Cell
lysates from a concomitant experiment were utilized in SBAP to assay the binding of hnRNP U
to 5’-biotinylated C9/E3 ROs. Cell lysate input for the SBAP was subjected to SDS-PAGE and
immunoblotted for hnRNP U and β-actin. (B) Overexpression of AKT decreases both caspase9a/9b ratio and hnRNP U-E3/C9 association. HBEpC cells were transfected with the control
adenovirus or the adenovirus expressing constitutive active AKT2 (caAKT2, 25 MOI) for 48
hours. Total protein or RNA extracts from the transfected cells were then subjected to SDSPAGE/immunoblotting or competitive/quantitative RT-PCR. Cell lysates were also generated for
SBAP to assay the binding of hnRNP U to E3/C9 ROs. The graphs shown in (A) and (B) are
representative of n=4 from three independent experiments.
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Figure 1.8 AKT inhibition does not alter the phospho-state of hnRNP U. (A) A549 cells
were treated with 0.1% DMSO control or AKT1/2 inhibitor (20 µM). Endogenous hnRNP U was
then immunoprecipitated (IP) and resolved by SDS-PAGE/ immunoblotting for phosphoserine/threonine or hnRNP U. (B) A549 protein extracts were incubated with denatured or active
CIP. Endogenous hnRNP U in the resulted protein extracts were immunoprecipitated (IP) and
resolved by SDS-PAGE/ immunoblotting for phospho-serine/threonine or hnRNP U. The graphs
shown in (A) and (B) are representative of n=3 from two independent experiments.
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Figure 1.9 AKT-dependent phosphorylation of hnRNP L leads to the competition with
hnRNP U for C9/E3 binding. (A) Phosphorylation of hnRNP L by AKT enhances binding to
E3/C9. Recombinant FLAG-tagged hnRNP L was phosphorylated in vitro using active AKT2
(denatured AKT2 was utilized as a negative control). Products from the kinase assay were then
subjected to SDS-PAGE/immunoblotting for phospho-serine/threonine, or the FLAG tag and
also utilized in the EMSA to examine the interaction with E3/C9 ROs. (B) AKT or EGFR
inhibition in NSCLC cells induces a reduction in the phospho-status of hnRNP L. A549 cells
were treated with either 0.1% DMSO control, AKT inhibitor (20 µM) or erlotinib (EGFR
inhibitor, 1 µM). Endogenous hnRNP L was immunoprecipitated (IP) from the protein extracts.
IPed hnRNP L was resolved by SDS-PAGE and immunoblotted with phospho-Ser52-hnRNP L or
hnRNP L antibodies. (C) Exogenous hnRNP L phosphorylated by AKT competes with
endogenous hnRNP U for binding to E3/C9. Recombinant hnRNP L was incubated with
denatured or active AKT2 in the in vitro kinase assay and then utilized in the SBAP-based
competitive binding assay using HBEpC cell lysates and E3/C9 ROs. (D) Model for controlling
hnRNPU-hnRNP L-E3/C9 interaction by AKT pathway. In the non-transformed cells, the
recruitment of hnRNP L to E3/C9 is interfered by hnRNP U binding to the same position.
Through activation of AKT pathway in transformed cells, hnRNP L is phosphorylated, which
results in the enhanced binding of this splicing repressor to E3/C9. Consequently, the elevated
levels of hnRNP L associated with E3/C9 prevent the access of hnRNP U to E3/C9 for spliceenhancing function. The graphs shown in (A), (B) and (C) are representative of n=4 from two
independent experiments.
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CHAPTER 4 – DISCUSSION:
REGULATION OF CASPASE-9 SPLICING BY HNRNP U

In this study, two additional C9/E3-associated proteins were identified by LC-MS/MS,
hnRNP R and hnRNP U. Whereas hnRNP R had no effect on caspase-9 splicing, hnRNP U was
revealed as a splicing enhancer and validated for interaction with C9/E3. To date, little is known
about the regulatory function of hnRNP U in RNA splicing although it is regarded as an RNAbinding protein. A recent study suggested that hnRNP U might be a global regulator of
alternative splicing; however, >90% of reported cases about an RNA splicing change induced by
hnRNP U down-regulation did not accompany binding to respective mRNA (69). Our findings
expand the situations where hnRNP U-regulated splicing events are associated with target
mRNA interactions.
The precise site for hnRNP U binding on C9/E3 was also examined. Previously, hnRNP U
has been reported to preferentially bind G/U-rich motifs in RNA (19, 34). In line with these
reports, hnRNP U was demonstrated to specifically interact with the G-rich sequence, GAGGG
in C9/E3. Furthermore, mutation of the upstream U-motif (UUUGAGGG) also significantly
reduced the association of hnRNP U with the C9/E3. Importantly, this sequence has been
reported as a binding site for hnRNP L. The opposing function of hnRNP U versus hnRNP L and
the same binding site on C9/E3 suggest regulatory competition between hnRNP U and hnRNP L
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and our data further suggest that the presence of hnRNP U likely restricts the exon-exclusion
effect of non-phosphorylated hnRNP L. Furthermore, the dramatic loss of protein:RNA complex
by mutation of this RNA cis-element suggests that hnRNP L and U may target additional RNA
trans-factors to exon 3. Current experimental directions are focused on determining whether the
phosphorylation of hnRNP L leads to loss or gain of binding partners, which aid in regulating the
inclusion/exclusion of the exon 3,4,5,6 cassette.
The nature of the regulation of the hnRNP U and L competition was also elucidated in this
study. For example, simple changes in expression of the RNA trans-factors did not account for
the observed loss of hnRNP U binding in transformed cells. Specifically, the expression of
hnRNP U and L were not significantly different between non-transformed and transformed cells.
Previous studies in our laboratory have pointed to the importance of phosphorylation in
regulating hnRNP L-C9/E3 interaction (21), and hnRNP U has been reported to be selectively
phosphorylated in response to DNA double-strand breaks (3, 6). Therefore, we hypothesized that
phosphorylation events might impact the association between hnRNP U and C9/E3.
Nevertheless, our findings in this study demonstrate that phosphorylation of hnRNP U is unlikely
to play a role, and the regulatory mechanism is mainly via phosphorylation of hnRNP L.
Together with the findings that caspase-9a/9b ratio is higher in non-transformed than in
transformed cells (21, 57) and the enhanced association of hnRNP U in non-transformed cells,
these data extend the mechanistic insights into the dysregulation of caspase-9 splicing in
transformed cells. In this paradigm, certain survival/oncogenic kinases are activated and
phosphorylate hnRNP L in transformed cells. As a result, the hnRNP L-C9/E3 interaction and
subsequent splice-repressing function is promoted while hnRNP U is prevented from binding and
competing with hnRNP L (Fig. 1.9D). Therefore, the exclusion of four-exon cassette is favored
30

shifting the alternative splicing of caspase-9 to the lower caspase-9a/9b ratio observed in NSCLC
cells.
Since the enhanced exclusion of exon 3,4,5,6 cassette has been linked to phosphorylation
events modulated by phosphoinositide 3-kinase/AKT pathway (Shultz 2010), this cell-survival
regulatory pathway likely mediates the phosphorylation of hnRNP L and subsequently the
competitive interaction between hnRNP L and hnRNP U to C9/E3. Indeed, inhibition of AKT
signaling in transformed cells augmented hnRNP U-C9/E3 binding, and the enhanced binding to
the C9/E3 were correlated perfectly with alteration in caspase-9 splice variant ratio. Hence, the
AKT pathway regulates the alternative splicing of caspase-9 via hindering the interaction
between hnRNP U and C9/E3 and subsequently suppressing its splice-enhancing function. Our
study also demonstrates that hnRNP L is a direct substrate for AKT, and thus, AKT may be
directly influencing the alternative splicing of caspase-9 via hnRNP L. Direct phosphorylation of
hnRNP L by AKT is not heretical as AKT has been shown to directly phosphorylate SRSF1
(SRp30a or ASF/SF2), another RNA trans-factor known to regulate the alternative splicing of
caspase-9 (57).
In regards to SRSF1 and caspase-9 RNA splicing, the presented study fills a missing “gap” in
our knowledge of how the exon 3,4,5,6 cassette is regulated. Previously, we reported that the
phosphorylation of SRSF1 on novel phosphorylation sites flanking the RS domain were partially
required for AKT activation to exclude the exon 3,4,5,6 cassette (57). Specifically, we showed
that a phospho-mimic of SRSF1 could only partially block the exclusion of the exonic cassette of
caspase-9 pre-mRNA induced by an AKT inhibitor. This study now places hnRNP L
phosphorylation and subsequent hnRNP U displacement from exon 3 as the plausible missing
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mechanism by which AKT activation maximally induces the exclusion of the exon 3,4,5,6
cassette.
One of the more intriguing findings is the observation that phosphorylation of hnRNP L
induces the association of the RNA trans-factor with a non-standard binding site. Numerous
reports in the literature have demonstrated that hnRNP L prefers CA-repeats. Indeed, we initially
found that recombinant hnRNP L did not bind the purine-sequence in-line with previous reports;
however, hnRNP L can be modulated to associate with different sequence specificity by
phosphorylation. Our data, therefore, suggest that hnRNP L may have both constitutive roles in
RNA splicing as well as activated roles in modulating a subset of splicing events. How
phosphorylation would change the sequence specificity of an RNA trans-factor has not been
described, but possibly one or more qRRM motifs could be “unmasked” by an intra-molecular
change in the structure of the RNA trans-factor stimulated by phosphorylation. This mechanism
is plausible as hnRNP K, a related RNA trans-factor, has been reported to have a qRRM that
does not recognize the standard GC-rich RNA sequence (46). Overall, phosphorylation may be a
key regulatory step in activating RNA splicing factors to induce specific RNA splicing events
(e.g. caspase-9 RNA splicing) in response to external stimuli outside of their roles in constitutive
RNA splicing.
In conclusion, our presented work implicates hnRNP U as a limiting factor for caspase-9b
formation, which has been previously demonstrated to enhance the anchorage-dependent growth
and tumorigenic capacity of non-small cell lung cancer (NSCLC) cells (21). Moreover, cascape9b is not significantly expressed in non-transformed cells (21), and the induction of caspase-9b
expression is due to activation of hnRNP L via phosphorylation to compete/inhibit hnRNP U
association with C9/E3. Therefore, targeting the phosphorylation of hnRNP L by specific kinase
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inhibitors to further augment the formation of apoptotic caspase-9a over anti-apoptotic caspase9b would be an attractive cancer-specific approach for treatment of NSCLC (50).
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CHAPTER 5 – INTRODUCTION:
MECHANISTIC FUNCTIONS OF CASPASE-9B IN THE NF-ΚB PATHWAY

5.1 Caspase-9b
As presented in 1.3, the alternative splicing of caspase-9 leads to the formation of two splice
variants and two corresponding isoforms, caspase-9a and caspase-9b. Lacking the catalytic site
but still containing the CARD domain in the structure confers caspase-9b the anti-apoptotic
capability (55, 59). Specifically, caspase-9b can bind to Apaf-1 via the CARD domain and
competes with caspase-9a for Apaf-1 association. Protection against apoptosis is also the onlyknown function of caspase-9b. Recently, caspase-9b has been reported to enhance the anchorageindependent growth and tumorigenic capacity of NSCLC cells (21), which indicates that besides
inhibiting apoptosis, caspase-9b may have activating roles in certain survival/oncogenic
pathway(s). Understanding the mechanisms of how caspase-9b augments the anchorageindependent growth and tumorigenic capacity of NSCLC cells would have significant
contribution to therapeutic development against lung cancer based on targeting caspase-9b.
5.2 NF-κB signaling: the canonical and non-canonical pathway
NF-κB refers to a family of transcription factors, Rel family, which plays important roles in
various biological processes including inflammation, immune response, cell growth control,
apoptosis

and

development

(24,

64).
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In

mammalian

cells,

five

NF-κB

proteins have been identified: RelA (p65), RelB, c-Rel, NF-κB1 (p105/p50) and NF-κB2
(p100/p50). These NF-κB proteins form different homodimeric or heterodimeric complexes that
can enter the nucleus, bind to the κB-enhancer sites and trans-activate numerous responsive
genes. For structural comparison, all five NF-κB proteins share a unique N-terminal Rel
homology domain (RHD) required for the formation of hetero- or homo-dimers and DNA
binding. However, only RelA, RelB and c-Rel has C-teminal transactivation domain (TAD),
which can activate the dimeric transcription factor complexes formed with p52 or p50. Since p52
and p50 both lacks TAD, their homo-dimers act as transcription repressors.
NF-κB dimers are normally sequestered in the cytoplasm by a family of inhibitors,
comprising IκB-α, IκB-β, IκB-γ, IκB-ε, NF-κB1 p105 (precursor) and NF-κB2 p100 (precursor).
The NF-κB inhibitors mask the nuclear localization signals (NLS) within NF-κB proteins and
capture them in the cytoplasm. The precursor NF-κB1and NF-κB2, p105 and p100, have the
IκB-like ankyrin-repeat domain, which thereby functions as NF-κB inhibitors. Proteosomal
processing of p105 and p100 not only generates the active NF-κB1 p50 and NF-κB2 p52 but also
abolishes the IκB-like action of the
precursor proteins.
There are two main arms of the NF-κB signaling, the canonical and noncanonical NF-κB
pathway (Fig. 2.1). The canonical NF-κB pathway is activated by a broad range of stimuli such
as inflammatory cytokines, lipopolysaccharides (LPS), growth factors or antigen receptors. The
limiting step in the canonical NF-κB pathway is the inducible degradation of IκB proteins,
particularly IκBα, which leads to nuclear transport of various NF-κB complexes, predominantly
the RelA-containing dimer. Upon canonical NF-κB activation, IκB-α is phosphorylated by the
IκB kinase (IKK), which is a trimeric complex
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composed of two catalytic subunits, IKK-α and IKK-β, and a regulatory subunit, IKK-γ (or NFκB essential modulator, NEMO). Phosphorylation of IκB-α results in its poly-ubiquitination and
proteasome-mediated degradation. The non-canonical NF-κB pathway is signaled through
particular TNF receptor family members that bind to the TNF receptor associated factors TRAF2
and/or TRAF3, such as LTβR, CD40, CD27, CD30, BAFF-R and RANK. Activation of the noncanonical pathway relies on NIK and IKKα-mediated phosphorylation and processing of NF-κB2
p100 precursor to p52, which then undergoes nuclear translocation of p52-containing dimers.
5.3 The roles of NF-κB activation in lung tumorigenesis and tumor progression
NF-κB is an inducible member of Rel family of transcription factors that regulate the
expression of more than 200 genes, many of which encode for anti-apoptotic proteins such as
Bcl-xL, cIAP1/2, A20, TRAF-2 and c-FLIP (32), regulatory factors in cell cycle control such as
cyclin D (26) and GADD45 (10), angiogenesis factors such as VEGF (vascular endothelial
growth factor), TNFα and MMPs (matrix metalloproteinases) (22, 42) and regulatory factors
involved in cell migration and adhesion such as VCAM-1 (vascular cell adhesion molecule-1),
ICAM-1 (intercellular adhesion molecule-1), CXCR4 (chemokine receptor) and uPA (serine
protease urokinase-type plasminogen activator) (22, 42). Therefore, NF-κB signaling may be
utilized by cancer cells to survive, proliferate, invade and metastasize. In fact, NF-κB pathway is
constitutively activated in a variety of cancers, including prostate, breast, cervical, pancreatic and
lung cancer (31, 40). Tumor samples from lung cancer patients present high levels of NF-κB
activation in both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) (29,
31). Furthermore, it has been reported that NF-κB activation contributes to lung tumor formation
and progression in mouse models (2, 14, 47) and also plays important roles in the invasion of
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lung cancer cells (11, 27). In sum, the correlation between lung cancer development and NF-κB
activation has been well-established.
5.4 Targeting NF-κB signaling for NSCLC treatment
Anti-cancer drugs have been showed to induce NF-κB activation in cancer cells, which
contributes to chemoresistance in these cells (30, 52, 66). Hence, NF-κB pathway is now an
attractive target for therapeutic design to sensitize cancer cells to apoptosis induced by chemical
therapy or to limit cancer invasion and metastasis. Current NF-κB inhibitors include natural or
synthesized compounds that target NF-κB signaling directly by targeting various
components/steps in the NF-κB pathway (e.s., activation of IKK, degradation of IκBα, nuclear
translocation and DNA binding of NF-κB complexes) or indirectly by targeting factors that
suppress/activate the NF-κB pathway (e.s., tumor suppressor p53, aurora kinases, heat shock
protein 90) (12). Several NF-κB inhibitors that sensitize lung cancer cells to chemical therapy
and radiation treatment are listed in Table 2.1. Interestingly, RNA aptamer targeting NF-κB1
p50 has been shown to inhibit NF-κB activation in NSCLC cells A549 and sensitize the cells to
apoptosis (48, 49). Nevertheless, there are concerns about using NF-κB inhibitors in cancer
therapy: 1) suppression of NF-κB signaling may impair immunity since NF-κB pathway plays
crucial roles in both innate and adaptive immunity; 2) the efficacy of NF-κB inhibitors varies in
different cells and tissues; and 3) NF-κB inhibitors may have off-target effects (e.s., inhibition of
NF-κB by proteasome inhibitors may affect the turnover of other proteins outside of NF-κB
pathway). Tremendous efforts have been made to develop an effective and selective NF-κB
inhibitor that can be used as a single or adjuvant agent to treat NSCLC.
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5.5 Specific aims of the study
The previously observed promoting effect of caspase-9b on the anchorage-independent
growth and tumorigenicity of NSCLC cells (21) leads to our hypothesis that caspase-9b activates
certain survival/oncogenic pathway(s) besides inhibitory roles on caspase-9a activation. In this
study, we found the survival/oncogenic NF-κB pathway as the potential target of caspase-9b. We
also determined the mechanistic roles of caspase-9b on each arm of the NF-κB pathways, the
canonical and non-canonical arm. We further examined the biological relevance of the functions
of caspase-9b in the NF-κB pathway, particularly the effects on cell survival, anchorageindependent growth and tumorigenicity of NSCLC cells.
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Table 2.1 NF-κB inhibitors sensitizing lung cancer cells to chemotherapeutics or ionizing
radiation (12) µ
NF-κB inhibitors

Correlative chemotherapeutics
ionizing radiation

Genistein

Cisplatin, docetaxel

Embelin

Paclitaxel

Curcumin

Vinorelbine

Knockdown of p65

Adriamycin

Expression of IκBα

Paclitaxel

Expression of mutant IκBα
(super repressor)

Cisplatin, gemcitabline, adriamycin,
etoposide

β-lapachone, nimesulide and MG132,
resveratrol, knockdown of TRAF2

Ionizing radiation
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or

Figure 2.1 The canonical and non-canonical pathway in the NF-κB signaling. The limiting
step in the canonical pathway is the proteosome-mediated degradation of IκB proteins, which
allows the nuclear translocation of p65-containing complexes. In the non-canonical pathway,
NF-κB activation is normally controlled by ubiquitination-mediated destabilization of NIK
protein, which prevents the proteosomal processing of the NF-κB2 p100 to p52 and further
inhibits the nuclear transport of p52-containing complexes.
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CHAPTER 6 – MATERIALS AND METHODS:
MECHANISTIC FUNCTIONS OF CASPASE-9B IN THE NF-ΚB PATHWAY

6.1 Cell culture
A549 and H838 lung adenocarcinoma cells were cultured in 50% DMEM and 50% RPMI
medium with 10% (v/v) FBS (Sigma-Aldrich), 100 U/ml penicillin and 100 µg/ml streptomycin
sulfate (Invitrogen). HEK 293 cells were cultured in DMEM medium with 10% (v/v) FBS
(Sigma-Aldrich), 100 U/ml penicillin and 100 µg/ml streptomycin sulfate (Invitrogen). Human
bronchial epithelial primary cells (HBEpC) were cultured in Bronchial/Tracheal Epithelial Cell
Growth medium (Cell Applications). All cells were maintained at less than 80% confluency
under standard incubator conditions.
6.2 siRNA transfection
A549, H838 or HBEpC cells were transfected with control siRNA or target siRNA for
caspase-9a, caspase-9b or c-IAP1 (Dharmacon) using Dharmafect 1 transfection reagent
(Dharmacon). Sequences of control or target si-RNA for caspase-9a or caspase-9b were listed in
Table 2.2. Cells (3-4 x 105) were plated in each well of 6-well tissue culture dishes in regular
growth medium. In the following day, cells were plated in Opti-MEM I medium without
antibiotics/FBS and transfected with 50 nM (for c-IAP1) or 100 nM (for caspase-9a or caspase9b) of siRNA (diluted in 1X siRNA buffer). In the next day, medium was changed to normal
growth medium. After 24 hours, cells were collected for further analysis or transfected with
adenovirus for additional 24 hours.
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6.3 Next-Generation RNA Sequencing and Expression Analysis
RNAs extracted from the cells using the RNeasy Mini Kit (Invitrogen) were sent to Nucleic
Acids Research Facilities, Virginia Commonwealth University, for Next-Generation Sequencing
(deep RNA sequencing). FASTQ files were analyzed using the Galaxy software and Tuxedo
protocol (62). Quality control of fragments was carried out using the FASTQC tool. Fragments
were mapped to a reference genome using Tophat, and merged using Cuffmerge. BAM files
were generated using Cufflinks and statistically significant transcripts were identified using
Cuffdiff. Resulting files were analyzed using Ingenuity Pathway Analysis in order to identify
differentially regulated pathways.
6.4 Plasmid transfection and selection of stable cell lines
Cell lines were transfected with plasmid vectors using Effectene Transfection Reagent
(Qiagen Inc.) following the manufacturer’s protocol. Briefly, cells were plated at approximately
40-60% confluency in 6-well plates or 100 mmm tissue culture dishes. The following day, cells
were transfected with plasmid constructs. After 24 hours of standard incubation, cells were used
in preparation of the protein extracts for Western immunoblotting or cell lysates for
immunoprecipitation (IP)/co-immunoprecipitation (coIP).
For stable cell selection, cells were plated at 1.5x104 cells in each well of 6-well plates. The
following day, cells were transfected with 1ug of plasmid using Effectene Transfection Reagent
(Qiagen Inc.). Cells were passaged into zeocin selection medium 24 hours after transfection and
consistently treated with zeocin for 2 weeks.
6.5 Nuclear and cytoplasmic extraction
Cytoplasmic and nuclear extracts were separated and prepared from cells using NE-PER
Reagents (Thermo scientific) following manufacture’s protocol. For preparation of nuclear
extract further used in DNA binding enzyme-linked immunosorbent assay (ELISA), the nuclear
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pellet was resuspended in complete lysis buffer provided by the TransAM® NFκB p52/p65
ELISA Kits (Active Motif) instead of the NE buffer in the NE-PER Reagents (Thermo
scientific).
6.6 Quantitative RT-PCR
Total RNA was extracted from the cells using the RNeasy Mini Kit (Invitrogen) and then
reverse transcribed to cDNA using SuperScript III Reverse Transcriptase Kit (Invitrogen). The
reverse transcription reaction products were utilized for real-time PCR for BIRC5, CXCR4, IRF3
and 18s using TaqMan PCR master mix and the Applied Biosystems 7500 Real-Time PCR
System. ID numbers for BIRC5, CXCR4, IRF3 and 18s q-PCR primers (Applied Biosystems)
were listed in Table 2.3. The relative amounts of BIRC5, CXCR4 and IRF3 were normalized to
18s.
6.7 DNA binding enzyme-linked immunosorbent assay (ELISA) for activated NFkB
transcription factors
DNA-binding capacity of NF-κB p52- or p65-containing complexes were evaluated by using
TransAM® NFκB p52/p65 ELISA Kits (Active Motif) and following the manufacturer’s
protocol. 5 µg of nuclear extract (in complete lysate buffer) was used for each well of the 96well plate in which oligonucleotides containing NF-κB consensus binding site had been
immobilized. The specific competitors (SC), which are the wild-type consensus oligonucleotides,
and the non-specific competitors (NSC), which are the mutated consensus oligonucleotides, were
utilized as the control for the specificity of the binding to the NF-κB consensus binding
sequence. The Jurkat or Raji nuclear extract was used also as the positive control for p65 or p52
activation, respectively.
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6.8 Immunoprecipitation (IP) and coimmunoprecipitation (coIP)
Cells were lysed in 1X coIP buffer containing 20 mM Tris-HCl pH 7.4, 150 mM NaCl, 1mM
EDTA pH 8.0, 0.5% NP-40 and 1X phosphatase/protease inhibitor cocktail. Cells used for
further immunoprecipitation of NIK were treated with 10 μM of proteasome inhibitor MG-132
for 1 hour before being lysed. For RIP, NIK or c-IAP1 immunoprecipitation/coimmunoprecipitation, 2 µl of RIP1, NIK or c-IAP1 monoclonal antibody was placed in each
sample (0.5-1 mg of total proteins) for 4-5 hours at 4oC with gentle agitation before 15 µl of prewashed protein A/G magnetic beads (Thermo scientific) were added and incubated at room
temperature for 10 minutes with gentle agitation. The bead complexes were washed 3 times with
1X coIP buffer, pelleted, resuspended in Laemmli buffer, incubated at room temperature for 10
minutes and the resulting supernatant were subjected to SDS-PAGE/immunoblotting. For myc or
FLAG co-immunoprecipitation, 15ul of pre-washed anti-FLAG M2 magnetic beads (Sigma) or
anti-Myc tag magnetic beads (Origene) were placed in each cell lysate sample for 3-4 hours at
4oC with gentle agitation. The bead complexes were washed 3 times with 1X coIP buffer,
pelleted and incubated with 60-80 μl of myc or 3X FLAG peptide (Sigma) solution for 45
minutes at 4oC to elute the myc/FLAG fusion proteins. Final concentration of peptides in elution
solution was 0.5 µg/ul in PBS with 1X phosphatase/protease inhibitor cocktail. The eluates were
directly used in the in vitro ubiquitination assay or subjected to SDS-PAGE/immunoblotting.
6.9 Cell survival assay (colony formation assay)
Cells were trypsinized and 150 cells were plated in each well of the 6-well plates in normal
growth medium (cells were plated on 3 wells for each occasion). Cells were incubated under
standard incubator conditions for 10-14 days before the colonies were fixed with methanol and
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stained with 0.05% crystal violet solution for 10 minutes. Then visually stained colonies were
counted.
6.10 Colony formation assay in soft-agar
Cells were trypsinized and a total of 2,000 cells in 1ml top agar (normal growth media
containing 0.35% agarose) were plated over 1.5 ml base agar layer (normal growth media
containing 0.6% agarose) in each well of 6-well plates (cells were plated on 3 wells for each
occasion). Cells were incubated under standard incubator conditions for 4 weeks before the
colonies were stained with 0.005% crystal violet for 1 hour. Stained colonies with diameters
larger than 100 μm were counted under a dissecting microscope. For colony size distribution,
images from each well of the soft-agar plates were taken and image J program was used to
calculate the average size of colonies.
6.11 In vitro ubiquitination assay
FLAG tagged cIAP1 or myc tagged wild-type/mutant caspase-9b was purified by
immunoprecipitation of FLAG or myc fusion proteins from HEK 293 cells transfected with
FLAG tagged cIAP1 plasmids or myc tagged wild-type/mutant caspase-9b plasmids for 24 hours
in normal growth medium and placed in serum-free medium for additional 6 hours. Purified
products of FLAG or myc immunoprecipitation from HEK 293 cells transfected with parental
empty plasmids were utilized also as the negative control. In vitro ubiquitination reactions were
performed at 37oC for 1 hour. The reaction mixtures (20 µl) included 50 nM E1 (Boston
Biochem E-305), 0.5 µM Ubc H5a E2 (E2-616), 1 μl FLAG tagged cIAP1 as E3 ligase or FLAG
negative control, 8 μl myc-tagged wild-type/mutant caspase-9b or myc negative control, 100 ng
recombinant tagged RIP1 (Abcam), 10 µM ubiquitin (Boston Biochem), 5 mM ATP, 50 mM
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Tris 7.5, 5 mM MgCl2 and 2 mM DTT. After incubation time, the product mixtures were
analyzed by Western immunoblotting.
6.12 Animals and tumor models
Six-week-old male C.B-17 SCID (IcrHsd-Prkdcscid) mice were purchased from Harland.
Animal experiments were conducted at Virginia Commonwealth University. The research
protocol (protocol number AD10000534) was approved by the VCU IACUC involving animal
care in accordance with the US Department of Agriculture (USDA) Animal Welfare
Regulations, the Public Health Service Policy on the Humane Care and Use of Laboratory
Animals, and the US Government Principles for the Utilization and Care of Vertebrate Animals
Used in Testing, Research, and Training. VCU is in compliance with all provisions of the
Animal Welfare Act and other federal statues and regulations relating to animals. VCU is
registered under the Animal Welfare Act as a class R research facility with the USDA Animal
and Plant Health Inspection Service (APHIS) Animal Welfare (registration number 52-R-0007).
The Office of Laboratory Animal Welfare (OLAW) approved the VCU Animal Welfare
Assurance in compliance with the Public Health Service Policy (assurance number A3281-01).
The SCID mice were acclimatized to the VCU Medical School Animal Facility for a week
before they received injections of cancer cells: 1.1x106 A549 human NSCLC cells were
resuspended in 100 μl DMEM and injected subcutaneously into the right hind flank. Tumors
were allowed to develop for up to 4 weeks and tumor size was measured every week by using a
caliper. After 4 weeks, mice were sacrificed and tumors were extracted and weighed.
6.13 Statistical analysis
Statistical differences between 2 objects were determined by a 2-tailed, unpaired Student’s t
test. Statistical differences among more than 3 objects were evaluated by one-way ANOVA
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followed by a Tukey’s HSD test. p values of less than or equal to 0.05 were considered
significant.
6.14 Adenovirus information
Adenovirus control (Vector Biolabs, catalog number 1300), adenovirus expressing IκB-α
(Vector Biolabs, catalog number 1504) or dominant negative IκB-αS (Vector Biolabs, catalog
number 1028) were used at 20-50 MOI. Adenovirus control or expressing caspase-9b were used
at 5 MOI for HBEpC cells, at 10 MOI for H838 cells and at 20-50 MOI for A549 cells. Higher
virus titer was used in A549 cells to obtain relatively the same level of protein expression.
6.15 Antibody information
The following antibodies were used in western immunoblotting, immunoprecipitation (IP) or
co-immunoprecipitation (co-IP): anti-caspase-9 (Assay Designs), anti-p65 (Cell Signaling
Technology),

anti-NF-κB2

(Cell

Signaling

Technology),

anti-IκB-α

(Cell

Signaling

Technology), phospho-IκB-α (Cell Signaling Technology), anti-β-actin (Sigma), anti-laminA/C
(Cell Signaling Technology), anti-α-tubulin(Cell Signaling Technology), anti-NIK (Cell
Signaling Technology), anti-RIP1 (Cell Signaling Technology), anti-ubiquitin (Cell Signaling
Technology), anti-cIAP1 (Cell Signaling Technology), anti-Apaf1 (Cell Signaling Technology),
anti-FLAG (Sigma), anti-myc (Cell Signaling Technology), horseradish peroxidase-conjugated
anti-rabbit IgG antibody (Cell Signaling Technology) and horseradish peroxidase-conjugated
anti-mouse IgG antibody (Cell Signaling Technology)
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Table 2.2 Control si-RNA for caspase-9a or caspase-9b, caspase-9a si-RNA and caspase-9b siRNA utilized in the study.
si-RNA name

Sequence

 Random control
 Mutant
caspase-9a
a mixture of 3 siRNA:
o Mutant caspase-9a 1
o Mutant caspase-9a 2
o Mutant caspase-9a 3
 Mutant caspase-9b control
 Caspase-9a,
a mixture of 3 siRNA:
o Caspase-9a 1
o Caspase-9a 2
o Caspase-9a 3
 Caspase-9b

GGAAUUCCAUCUAGCUCAAACUU
control,
ACCAGUGGCACUACUGCGGUUUU
CAUCAGAAGAACUGCGGUGAGUU
CACUAGACGCGUGAGGCCAGGUU
GUAUAGGACAUCACGACGAUAUU
AACAAUGUGAACUUCUGCCGUUU
AAUGUGAACUUCUGCCGUGAGUU
AACUUCUGCCGUGAGUCCGGGUU
GAUUUGGUGAUGUCGAGCAUUUU
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Table 2.3 qPCR primers specific for NF-κB target genes.
Gene

ID number

BIRC5

Hs04194392_s1

CXCR4

Hs00607978_s1

IFR3

Hs01547283_m1

18S

Hs99999901_s1

49

CHAPTER 7 – RESULTS:
MECHANISTIC FUNCTIONS OF CASPASE-9B IN THE NF-ΚB PATHWAY

7.1 Identification of NF-κB as the signaling pathway of caspase-9b target
Until now, the only-known function of caspase-9b is protection against apoptosis by
inhibition of caspase-9a processing (44, 48). Since expression of caspase-9b has previously
demonstrated to augment tumorigenicity of NSCLC cells, caspase-9b expression might have a
“gain of function” phenotype or in other words, activate survival/oncogenic pathways outside of
its inhibitory effect on caspase-9a function. Therefore, high throughput next-generation
sequencing (deep RNA sequencing) has been performed to identify cell signaling pathways as
plausible targets of caspase-9b and deep RNA sequencing analysis has revealed a potential link
between caspase-9b and the NF-κB pathway. Specifically, down-regulation of caspase-9b affects
expression of various genes, which have been shown in literature to be related to the up-stream
or down-stream of the NF-κB pathway (figure 2.2 and table 2.4). Furthermore, nearly 40% of
these genes are NF-κB responsive genes (table 2.5). The finding of NF-κB as a potential pathway
of caspase-9b target suggests that caspase-9b might regulate the survival/oncogenic NF-κB
pathway and affecting the NF-κB pathway might contribute to caspase-9b-mediated
enhancement of tumorigenic capacity of NSCLC cells.
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7.2 Caspase-9b activates the canonical and inhibits the noncanonical NF-κB pathway
The roles of caspase-9b in the NF-κB signaling were further validated. In the NF-κB
pathway, p65- or p52-containing complexes are the dominant complexes in the canonical or
noncanonical arm and activation of the canonical or noncanonical arm leads to the nuclear
transport of p65 or p52 complexes, respectively. As shown in figure 2.3A and B, knocking down
of caspase-9b resulted in less p65 but more p52 translocated into the nucleus and expressing
caspase-9b increased the nuclear p65 level but decreased the level of nuclear p52. In correlated
with the nuclear translocation, caspase-9b impacts, in a contrasting manner, the expression of the
canonical versus non-canonical NF-κB target genes (figure 2.3C and D). More p65 or less p52 in
the nucleus of the caspase-9b-reduced cells also leads to more p65 or less p52 binding to DNAs
containing NF-κB responsive sites (figure 2.3E and F). Together, these findings indicate the
opposite roles of caspase-9b in two arms of the NF-κB pathway, activating the canonical and
inhibiting the noncanonical arm.
The limiting step in the canonical NF-κB pathway is the phosphorylation-mediated turn-over
of IκB proteins, particularly IκB-α, whereas activation of the noncanonical pathway relies on
stabilization of NIK and processing of NF-κB2 p100 precursor to p52. Hence, NF-κB2 p100
processing and the level of IκB-α and NIK were evaluated when caspase-9b is up- or downregulated. As a result, caspase-9b was shown to dramatically promote the the processing of NFκB2 p100, phosphorylation and degradation of IκB-α (figure 2.4A and B). Caspase-9b was also
shown to impact the ubiquitination and turn-over of NIK (figure 2.4C, D and E). Since it has
been reported that NIK is tightly controlled by ubiquitination- and proteasome-mediated
degradation (41), the observed increase in NIK level (figure 2.4C and D) and decrease in NIK
ubiquitination (figure 2.4E) as caspase-9b is down-regulated supports our model where caspase-
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9b prevents the noncanonical NF-κB activation by elevating the ubiquitination and degradation
of NIK. Caspase-9b down-regulation not only affected NIK ubiquitination, it also decreased
RIP1 ubiquitination (figure 2.4E). RIP1 is a crucial factor in the NF-κB signaling, of which
ubiquitination has been known to positively regulate the canonical NF-κB pathway (15, 33, 67),
contrary to ubiquitination of NIK and consequent non-canonical NF-κB repression (41).
Therefore, these findings further solidify the dual actions of caspase-9b in the NF-κB signaling:
on one hand, caspase-9b stimulates RIP1 ubiqutination and enhances phosphorylation-mediated
degradation of the IκB-α, freeing p65-containing complexes to translocate into the nucleus for
gene transcription; on the other hand, caspse-9b facilitates ubiquitination-mediated degradation
of NIK and thereby prevents the processing and nuclear transport of the NF-κB2, which then
keeps the non-canonical NF-ΚB in an off-state.
7.3 Caspase-9b enhances the survival and anchorage-independent growth (AIG) capability
of NSCLC cells by activation of the canonical NF-κB pathway
Caspase-9b expression has been demonstrated to promote the anchorage-independent growth
(AIG) and tumorigenic capacity in NSCLC cells (21). In accordance with the literature, downregulation of caspase-9b resulted in a decrease of cell survival and stable expression of caspase9b increased the survival of NSCLC cells (figure 2.5A and B). Due to the activating roles of
caspase-9b in the oncogenic/survival NF-κB pathway, i.e. the canonical pathway, it is likely that
activation of the canonical NF-κB contributes to the enhancement of cell survival by caspase-9b.
In order to address that hypothesis, the NF-κB suppressor IκB-α or the dominant-negative
suppressor (or super repressor), IκB-αS, was expressed in the NSCLC cells followed by
expression of caspase-9b. Repression of the canonical NF-κB by expression of the suppressor or
super suppressor both led to a significant decrease in cell survival and only the suppressing effect
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of the IκB-α on the survival was rescued by caspase-9b expression (figure 2.5C). Additionally,
caspase-9b expression enhanced the degradation of IκB-α but had no effect on IκB-αS level
(figure 2.5C), which might explain the rescue of cell survival by caspase-9b expression only
toward IκB-α expression. Another approach was utilized to determine the biological relevance of
the NF-ΚB activating roles of caspase-9b, particularly focusing on the cell survival and AIG: the
suppressor or super suppressor was expressed in the control cells or cells stably expressing
caspase-9b. For the control cells, expression of either suppressor IκB-α or super suppressor IκBαS resulted in a decrease of colony formation in both conditions, with or without soft-gar but for
the cells stably expressing caspase-9b, only expression of the non-degradable IκB-αS reduced the
number of colonies formed (figure 2.5D). Importantly, cells stably expressing caspase-9b had
lower level of IκB-α but the same level of IκB-αS compared to control cells (figure 2.5D), which
is in agreement with all findings above and the hypothesis that caspase-9b augments the cell
survival and AIG by facilitating degradation of IκB-α and consequent canonical NF-κB
activation.
7.4 cIAP1 plays critical roles in caspase-9b-mediated NF-κB activation/inhibition
The roles of caspase-9b in both canonical and non-canonical NF-κB pathway give rise to a
possibility that caspase-9b might interact with certain regulatory factors that mediate the crosstalk between two arms of the signaling pathway. In this regard, cellular inhibitors of apoptosis
(cIAPs) are of interest since c-IAP proteins have been known to have functions in both canonical
and non-canonical pathway (5, 28, 44, 64, 65, 71). Validated by our study, down-regulation of cIAP1 had similar effects as caspase-9b on the NF-κB signaling. c-IAP1 down-regulation
increased the processing of the NF-κB2 p100 to p52 and the level of both NIK and IκB-α (figure
2.6A). Furthermore, c-IAP1 depletion altered the level of nuclear p65 and p52, specifically
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decreased p65 and increased p52 level (figure 2.6B). Down-regulation of c-IAP1 also reduced
the ubiquitintation of RIP1 and NIK (figure 2.6C). All of these findings indicate that c-IAP1
might mediate the effects of caspse-9b on NF-ΚB signaling and the lung cancer cell survival.
The above hypothesis was supported by results showing that down-regulation of c-IAP1
abolished the activating/inhibitory effects of caspase-9b on the NF-ΚB pathway, particularly the
level of NIK and IκB-α (figure 2.7A and B) and the ubiquitination of RIP1 and NIK (figure
2.7C). Importantly, c-IAP1 depletion also abrogated the enhanced cell survival conferred by
caspase-9b expression (figure 2.7D). Taken together, it is likely that c-IAP1 mediates the action
of caspase-9b on the NF-κB signaling to enhance the survival of NSCLC cells.
7.5 Caspase-9b directly binds to c-IAP1
Several proteins of the inhibitor of apoptosis protein (IAP) family members, particularly
XIAP and c-IAP1/2, have been known to associate with the processed caspase-9 via the IAPbinding motif (IBM) motif on caspase-9 (16, 59). This four-residue motif has been conserved
during evolution and it is also present in the IAP-interacting protein Smac/DIABLO of
human/mice and in a group of pro-apoptotic factors, Reaper, head-involution defective (Hid),
Grim and sickle (Skl), of Drosophila (hence, also known as Reaper–Hid–Grim, RHG, motif)
(59). The truncated caspase-9b still retains the IBM and thereby possibly binds to c-IAP1 to
modulate the NF-κB signaling. This possible direct interaction was validated by
coimmunoprecipitation of the endogenous c-IAP1 and ectopically expressed caspase-9b (figure
2.8A). Furthermore, mutation on caspase-9b at IBM (sequence shown in figure 2.8B) reduced
the association between c-IAP1 and caspase-9b (figure 2.8C) but did not interfere with the
interaction between caspase-9b and Apaf-1 (figure 2.8D), which suggests that mutant caspase-9b
is structurally intact and IBM on caspase-9b is crucial for c-IAP1 binding. Interestingly, although
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caspase-9 has been reported to bind to XIAP or c-IAP1/2 only if being processed (16, 59), our
results indicate that full-length caspase-9b (37 KDa) still binds to c-IAP1. Additionally,
mutations of caspase-9b at the cleavage sites had no effects on its interaction with c-IAP1 (figure
2.9A). It is plausible that whereas caspase-9 needs to be cleaved to expose the IBM for c-IAP1/2
binding, the truncated caspase-9b has already had the IBM exposed; thus, no more processing is
necessary.
The residue(s) on c-IAP1 required for caspse-9b binding has also been revealed. It has been
reported that residues in BIR2 and BIR3 domain of c-IAP1 are critical for caspase-9 interaction
(16). Therefore, these residues were mutated to examine if they are also required for caspase-9b
binding (sequences indicated in figure 2.10A). Interestingly, only one out of four mutations,
mutation at D320 on BIR3 of c-IAP1, was shown to abolish caspase-9 binding. Importantly,
D320A mutation did not affect c-IAP1 interaction with RIP1 (figure 2.10B), which ruled out the
possibility that D320A mutation impaired the whole c-IAP1 structure. These findings point to the
importance of residue(s) on BIR3 domain of c-IAP1 for interaction with caspase-9b.
7.6 Caspase-9b regulates the NF-κB pathways and promotes the survival and
tumorigenicity of NSCLC cells via direct interaction with c-IAP1
To examine whether the association of caspase-9b to c-IAP1 is essential for caspase-9bmediated NF-κB activation/inhibition, mutated caspase-9b at IBM, which was showed to have
remarkably reduced binding to c-IAP1 (figure 2.8C), was expressed and NIK/IκB-α level was
evaluated. As shown in figure 2.11A, expression of IBM-mutated caspase-9b did not
significantly affect NIK and IκB-α level as expression of wild-type caspase-9b. This finding was
congruent with the observation that mutation of caspase-9b at cleavage site(s), which was not
shown to affect caspase-9b binding to c-IAP1, was also not shown to affect the capability of
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caspase-9b to regulate NIK and IκB-α level (figure 2.9B). Mutation of caspase-9b at IBM also
resulted in loss of enhancing effect of caspase-9b on the survival (figure 2.11B) and AIG of
NSCLC cells (figure 2.11C). At tumor formation level, NSCLC cells expressing wild-type
caspase-9b formed tumors in mice with dramatically higher volume and weight compared to
control cells or cells expressing mutated caspase-9b (figure 2.11D). Most important, only
expression of wild-type caspase-9b but not of mutated caspase-9b rescued the reduced survival
and AIG of NSCLC cells as a result of caspase-9b depletion (figure 2.11E, F and G). Overall, via
binding to c-IAP1, caspase-9b affects both arms of the NF-κB signaling and enhances the
survival and tumorigenicity of the NSCLC cells.
7.7 Caspase-9b augments the E3 ligase activity of c-IAP1
Given that the E3 ligase activity of c-IAP1 impacts ubiquitination of RIP1 and
ubiquitination-mediated degradation of NIK (4, 5, 64, 71), caspase-9b likely binds to c-IAP1 and
promotes its E3 ligase activity. Supporting to this plausible mechanism, co-expression of wildtype caspase-9b and c-IAP1 was showed to induce the ubiquitination of RIP1 and NIK in a
significantly higher magnitude than expression of either wild-type caspase-9b or c-IAP1 alone
(figure 2.12A and B). Addition of caspase-9b into the in vitro ubiquitination assay dramatically
increased the E3 ligase activity of c-IAP1 (figure 2.12C). Furthermore, the enhancing effect of
caspase-9b on c-IAP1-mediated ubiquitination was diminished when caspase-9b/c-IAP1 binding
was interfered by mutation of caspase-9b at IBM (figure 2.12A, B and C). These findings shed
light on how interaction between c-IAP1 and caspase-9b facilitates the roles of caspase-9b in the
NF-κB pathways: through binding to c-IAP1, caspase-9b enhances its E3 ligase activity to
induce ubiquitination of RIP1 for the canonical NF-κB activation and ubiquitination of NIK for
turning off the non-canonical pathway (figure 2.12D).
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Table 2.4 List of NF-κB-related genes that expression is affected by down-regulation of caspase9b (identified by deep RNA sequencing analysis)
Gene name
BAD
BAX
BCL2A1
BCL2L1
BCL2L2
BIRC2
BIRC3
BMI1
C3
CASP8
CCL2
CCL3
CCL5
CCNB2
CCND1
CD44
CDC25B
CDKN1A
CFLAR
CLU
CREB3
CSNK2A1
CXCL1
CXCL2
CXCL3
CXCL8
CXCL10
ELF3
EMR1
ERAP1
ERBB2
FAS
FTH1
FUCA1
GDF15
HMOX1
ICAM1
IER3
IFNL1
IL15RA
IRF1
IRF7

Gene ID
572
581
597
598
599
329
330
648
718
841
6347
6348
6352
9133
595
960
994
1026
8837
1191
10488
1457
2919
2920
2921
3576
3627
1999
2015
51752
2064
355
2495
2517
9518
3162
3383
8870
282618
3601
3659
3665
57

JUNB
LITAF
MCL1
MICA
MYC
NAMPT
NFKB2
NFKBIA
NFKBIZ
NOP14
PLAU
PLK1
PTGS2
RRAS2
SDC4
SENP1
SENP2
SMAD3
SOAT1
SOCS1
SOCS3
SOD2
TCF12
TFPI2
TGFB1
TGM2
TNFAIP8
TNFRSF10B
TNFRSF1A
TNIP1
TP53
TRAF2
TRIB3
WTAP
XIAP

3726
9516
4170
100507436
4609
10135
4791
4792
64332
8602
5328
5347
5743
22800
6385
29843
59343
4088
6646
8651
9021
6648
6938
7980
7040
7052
25816
8795
7132
10318
7157
7186
57761
9589
331
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Table 2.5 List of NF-κB target genes that expression is affected by down-regulation of caspase9b (identified by deep RNA sequencing analysis)
Gene name
BAX
BCL2A1
BCL2L1
BMI1
C3
CCL2
CCL3
CCL5
CCND1
CD44
CDKN1A
CFLAR
CREB3
CXCL1
CXCL3
CXCL10
ELF3
ERAP1
ERBB2
FAS
FTH1
HMOX1
ICAM1
IER3
IRF1
IRF7
JUNB
MICA
MYC
NAMPT
NFKB2
NFKBIA
NFKBIZ
NOP14
PLAU
PTGS2
SDC4
SENP2
SOD2
TFPI2
TGM2
TNFAIP8

Gene ID
581
597
598
648
718
6347
6348
6352
595
960
1026
8837
10488
2919
921
3627
1999
51752
2064
355
2495
3162
3383
8870
3659
3665
3726
100507436
4609
10135
4791
4792
64332
8602
5328
5743
6385
59343
6648
7980
7052
25816
59

TNFRSF10B
TNFRSF1A
TNIP1
TP53
TRAF2
XIAP

8795
7132
10318
7157
7186
331
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Figure 2.2 Deep sequencing reveals NF-κB as the signaling pathway affected by caspase-9b.
A549 cells were transfected with random control, mutant caspase-9b control or caspase-9b
siRNA for 48 hours. (A) Total RNA were isolated and analyzed by deep RNA sequencing. The
graph represents all NF-κB-related genes, of which expression was significantly different
between control samples (random or mutant caspase-9b) and caspase-9b-down-regulated
samples. Red, up-regulated genes; green, down-regulated genes; higher color intensity indicates
higher difference in expression level; solid line arrows, genes/factors directly affecting/affected
by NF-κB transcription complexes; dashed line arrows, genes/factors indirectly
affecting/affected by NF-κB transcription complexes. Cell localization of these NF-κB-related
factors was also indicated. (B) Total proteins were prepared and subjected to SDSPAGE/immunoblotting for caspase-9 or β-actin. The graphs shown in (A) and (B) are
representative of n=4 from two independent experiments.
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Figure 2.3 Caspase-9b affects expression of NF-κB target genes, nuclear translocation and
DNA binding activity of NF-κB proteins. (A and B) Caspase-9b has effects on the nuclear
transport of p65 and p52. (A) Cytosolic/ nuclear fractions were prepared from A549 cells
transfected with random control, mutant caspase-9b control or caspase-9b siRNA for 48 hours
(A) and from A549 control cells or cells stably expressing caspase-9b (B). Cytosolic/nuclear
protein extracts were subjected to SDS-PAGE/immunoblotting for NF-κB p65, NF-κB2, lamin
A/C or α-tubulin. (C and D) Caspse-9b affects the expression of NF-κB target genes. Total RNA
was isolated from A549 cells transfected with random control, mutant caspase-9b control or
caspase-9b siRNA and relative amount of the canonical (A) or noncanonical (B) NF-κB targets
was determined by quantitative RT-PCR. (E) DNA binding ELISA for NF-κB p65 or p52 were
performed using nuclear extracts from A549 cells transfected with random control, mutant
caspase-9b control or caspase-9b siRNA for 48 hours. Specific or nonspecific competitors (SC or
NSC) were also utilized. Nuclear extracts from Jurkat or Raji cells were used as positive control
for p65 or p52 activation. (F) Nuclear extract input in (E) was subjected to SDSPAGE/immunoblotting for NF-κB p65, NF-κB2 or lamin A/C. Data are shown as means ± SD
(n=6 on 2 independent occasions). Statistical significance was evaluated by one-way ANOVA
followed by a Tukey’s HSD test (#p<0.05, ##p<0.01, *p<0.005, **p<0.001). Experiments in (A)
and (B) were repeated at least twice.
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Figure 2.4 Caspase-9b promotes the processing, turn-over and ubiquitination of proteins in
the NF-κB signaling. (A and C) Down-regulation of caspase-9b increases the processing of NFκB2 p100 to p52 and the level of IκB-α (A) as well as NIK protein (C). A549 cells transfected
with random control, mutant caspase-9a control, caspase-9a, mutant caspase-9b or caspase-9b
siRNA for 48 hours. Total protein extracts were subjected to SDS/PAGE/immunoblotting for
NF-κB2 p100/p52, IκB-α, caspase-9, NIK or β-actin. (B and D) Caspase-9b expression
decreases the processing of NF-κB2 p100 to p52 and the level of IκB-α (B) as well as NIK
protein (D). A549 cells were transfected with parental empty or C9b-expressing plasmids for 24
hours. Total protein extracts were subjected to SDS/PAGE/immunoblotting for NF-κB2
p100/p52, phospho-IκB-α, IκB-α, caspase-9, NIK or β-actin. (E) Down-regulation of caspase-9b
decreases the unbiquitination of RIP1 and NIK proteins. A549 cells were transfected with
random control, mutant caspase-9b control or caspase-9b siRNA for 48 hours. Endogenous
RIP1or NIK was immunoprecipitated (IP) from cell lysates and resolved by SDS-PAGE/
immunoblotting for ubiquitin, RIP1 or NIK. All experiments were repeated at least twice.
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Figure 2.5 Activation of the canonical NF-κB pathway contributes to caspase-9b-mediated
enhancement of the survival and anchorage-independent growth of NSCLC cells. (A, B, C
and D) Colony formation assays were performed with A549 cells transfected with random
control, mutant caspase-9b control or caspase-9b siRNA for 48 hours (A), with A549 control or
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caspase-9b-stably-expressing cells (B), with A549 cells transfected with control adenovirus or
adenovirus expressing IκB-α or super suppressor IκB-α (IκB-αS) for 24 hours followed by 24hour transfection with control adenovirus or adenovirus expressing caspase-9b (C), with A549
control or caspase-9b-stably-expressing cells transfected with control adenovirus or adenovirus
expressing IκB-α or super suppressor IκB-α (IκB-αS) for 24 hours (D). Western immunoblotting
of total protein extracts from cells in each case were also performed for caspse-9, IκB-α, IκB-αS
or β-actin. (E) Colony formation assays in soft-agar were carried out using A549 cells as in (D).
The graph presents the average number of colonies on each well of the 6-well plates.
Representative fields of the soft-agar plates were shown in the microscopic images below the
graphs, (*) scale bar, 2 mm. Data are shown as means ± SD (n=6 on 2 independent occasions).
Statistical significance was evaluated by one-way ANOVA followed by Tukey’s HSD test
(#p<0.05, ##p<0.01, *p<0.005, **p<0.001).
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Figure 2.6 Down-regulation of cIAP1 has similar effects on the NF-κB pathway with downregulation of caspase-9b. A549 cells were transfected with control or c-IAP1 siRNA for 48
hours. (A) Total protein extracts were prepared and subjected to SDS/PAGE/immunoblotting for
cIAP1, NIK, NF-κB2 p100/p52, IκB-α or β-actin. (B). Cytosolic/nuclear protein extracts were
prepared and subjected to SDS-PAGE/immunoblotting for NF-κB p65, NF-κB2, lamin A/C or αtubulin. (C) Endogenous RIP1or NIK was immunoprecipitated (IP) from cell lysates and
resolved by SDS-PAGE/ immunoblotting for ubiquitin, RIP1 or NIK. All experiments were
repeated at least twice.
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Figure 2.7 Down-regulation of cIAP1 abrogates the activating/inhibitory effect of caspase9b on the NF-κB signaling. A549 cells were transfected with control or c-IAP1 siRNA for 48
hours followed by 24-hour transfection with control adenovirus or adenovirus expressing
caspase-9b. (A) Total protein
extracts
were prepared
and subjected to
SDS/PAGE/immunoblotting for cIAP1, caspase-9, IκB-α, NIK or β-actin. (B) Graphs were
created by densitometry calculation of the results in (A). Data in (B) are shown as means ± SD
(n=3). Statistical significance was evaluated by one-way ANOVA followed by a Tukey’s HSD
test (#p<0.05, ##p<0.01, *p<0.005, **p<0.001). (C) Endogenous RIP1or NIK was
immunoprecipitated (IP) from cell lysates and resolved by SDS-PAGE/ immunoblotting for
ubiquitin, RIP1 or NIK. (D) Colony formation assays were carried out from the above cells. Data
in (D) are shown as means ± SD (n=6 on 2 independent occasions). Statistical significance was
evaluated by one-way ANOVA followed by Tukey’s HSD test (#p<0.05, ##p<0.01, *p<0.005,
**p<0.001). Experiments in (A), (B) and (C) were repeated at least twice.
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Figure 2.8 Caspase-9b directly binds to c-IAP1 via the IAP-binding motif. (A) Caspase-9b
associates with cIAP1. A549 cells were transfected with parental empty plasmid or plasmid
expressing myc-tagged caspase-9b. Endogenous cIAP1 or myc-tagged caspase-9b was
coimmunoprecipitated (coIP) from cell lysates and resolved by SDS-PAGE/ immunoblotting for
c-IAP1 or myc. Input was immunoblotted for c-IAP1, myc or β-actin. IgG was also used as the
control. (B) Schematic representation of protein structure for caspase-9a and caspse-9b.
Compared to caspase-9a, caspase-9b lacks most of the large subunit, including the catalytic site,
but retains the caspase recruitment domain (CARD), linker region (LR) and small subunit. The
LR contains the cleavage sites (closed triangle indicates the auto-cleavage site and opened
triangle indicates the site for caspase-3-mediated cleavage) and a conserved IAP-binding motif
(IBM). Sequences of the wild-type (WT) and mutated (Mut) IBM utilized the study were
indicated in the text box. (C and D) Mutation at IBM disrupts caspase-9b binding to c-IAP1 but
not to Apaf-1. (C) A549 cells were co-transfected with FLAG-tagged cIAP1 and parental empty
plasmid or plasmid expressing myc-tagged wild-type (WT) or mutated caspase-9b at the IBM for
24 hours. FLAG-tagged cIAP1 was coimmunoprecipitated (coIP) from cell lysates and resolved
by SDS-PAGE/ immunoblotting for FLAG or caspase-9. (D) A549 cells were co-transfected
with FLAG-tagged Apaf-1 and parental empty plasmid or plasmid expressing myc-tagged wildtype (WT) or mutated caspase-9b at the IBM for 24 hours. FLAG-tagged Apaf-1 was
coimmunoprecipitated (coIP) from cell lysates and resolved by SDS-PAGE/ immunoblotting for
FLAG or caspase-9. All experiments were repeated at least twice.
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Figure 2.9 Cleavage of caspase-9b is unimportant for interaction with cIAP1. (A) A549 cells
were co-transfected with FLAG-tagged cIAP1 and parental empty plasmid or plasmid expressing
myc-tagged wild-type (WT) or mutated caspase-9b at the cleavage sites (D166A, D181A) for 24
hours. FLAG-tagged cIAP1 was coimmunoprecipitated (coIP) from cell lysates and resolved by
SDS-PAGE/ immunoblotting for FLAG or caspase-9. Myc tagged full-length caspase-9b (37
KDa, p37) can be cleaved into p10 and myc tagged p27 subunit (if being cleaved at D166 site) or
into p12 and myc tagged p25 subunit (if being cleaved at D181 site). NS, non-specific band. (B)
A549 cells were transfected with parental empty plasmid or plasmid expressing myc-tagged
wild-type (WT) or mutated caspase-9b at the cleavage sites for 24 hours and total protein
extracts were prepared and subjected to SDS/PAGE/immunoblotting for NIK, caspase-9, IκB-α
or β-actin. All experiments were repeated at least twice.
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Figure 2.10 A residue in BIR3 domain of cIAP1 is critical for the association with caspase9b. (A) Schematic of c-IAP1 structure. Critical residues for caspase-9 binding have been
identified mostly in the BIR2 and BIR3 domain of c-IAP1 (white rectangles). c-IAP1 mutations
utilized in the study were indicated in the text box. (B) A549 cells were co-transfected with myctagged caspase-9b and parental empty plasmid or plasmid expressing FLAG-tagged wild-type
(WT) or mutated (Mut) cIAP1 in BIR2 domain or BIR3 domain for 24 hours. FLAG-tagged
cIAP1 was coimmunoprecipitated (coIP) from cell lysates and resolved by SDS-PAGE/
immunoblotting for cIAP1, RIP1 or caspase-9. Experiments were repeated at least twice.
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Figure 2.11 Direct binding to cIAP1 is essential for caspase-9b-mediated NF-κB
activation/inhibition. (A) A549 cells were transfected with parental empty plasmid or plasmid
expressing myc-tagged wild-type (WT) or mutated caspase-9b at IBM for 24 hours and total
protein extracts were prepared and subjected to SDS/PAGE/immunoblotting for NIK, caspase-9,
IκB-α or β-actin. (B) Colony formation assays were performed from stable control cells (A549)
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or cells stably expressing myc-tagged wild-type (WT) or mutated caspase-9b at IBM. (C) Colony
formation assays on soft agar were carried out using cells as in (B). The graphs present the
colony size distribution and the average number of colonies on each well of the 6-well plate.
Representative fields of the soft-agar plates and representative colonies were shown in the
microscopic images below the graphs, (*) 2 mm scale bar, (**) 400 μm scale bar. (D) Cell lines
in (B) or (C) were injected into right flanks of the SCID mice (1.1 × 106 cells/mice). Tumor size
was measured every week. After 4 weeks, mice were sacrificed and tumor weight was evaluated.
Data are shown as mean ± SD (n=8). Statistical significance was evaluated by one-way ANOVA
followed by Tukey’s HSD test (For the left graph, *p<0.005, **p<0.001, WT caspase-9b versus
control or mutated caspase-9b; for the right graph, #p<0.05, *p<0.005). (E, F and G) A549 cells
were transfected with random control, mutant caspase-9b control or caspase-9b siRNA for 48
hours followed by 24 hour transfection with parental empty plasmid or caspase-9b-siRNAresistant plasmid expressing myc-tagged wild-type (WT) or mutated caspase-9b. (E) Total
protein extracts were prepared and subjected to SDS/PAGE/immunoblotting for caspase-9, IκB-α
or β-actin. (F) Colony formation assays were performed. (G) Colony formation assays on soft
agar were carried out as in (C). Data are shown as means ± SD (n=5 for experiments in panel B
and n=6 for experiments in panel C, F and G). Statistical significance was evaluated by one-way
ANOVA followed by Tukey’s HSD test (#p<0.05, ##p<0.01, *p<0.005, **p<0.001).
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Figure 2.12 Caspase-9b enhances E3 ligase activity of c-IAP1 via direct interaction. (A and
B) Caspase-9b/cIAP1 binding increases the ubiquitination of RIP1 (A) and NIK (B). A549 cells
were transfected with a combination of parental control plasmid/ plasmid expressing FLAGtagged cIAP1 and myc-tagged wild-type (WT)/mutated (Mut) caspase-9b at IBM for 24 hours.
FLAG-tagged cIAP1 was coimmunoprecipitated (coIP) from cell lysates and resolved by SDSPAGE/ immunoblotting for ubiquitin, RIP1 or NIK. Input was immunoblotted for c-IAP1,
caspase-9 or β-actin. (C) Wild-type caspase-9b but not IBM-mutated caspase-9b increases E3
ligase activity of c-IAP1. In vitro ubiquitination assay was performed using E1 activating
enzyme and E2 conjugating enzyme in the presence or absence of FLAG tagged cIAP1 (E3
ligase) and myc tagged wild-type (WT) or mutated (Mut) caspase-9b. FLAG tagged cIAP1, myc
tagged WT or Mut caspase-9b was purified by immunoprecipitation (IP) of FLAG/myc fusion
proteins from cells transfected with plasmid expressing FLAG-cIAP1 or myc-WT/Mut caspase9b. In the absence of FLAG-cIAP1 or myc-WT/Mut caspase-9b, FLAG- or mycimmunoprecipitated products from cells expressing parental empty plasmid were used as
controls. (D) Mechanistic model of how caspase-9b regulates the NF-κB signaling and
promotes the survival and anchorage-independent growth capacity of NSCLC cells. In this
model, caspase-9b directly binds to c-IAP1 via the IBM on caspase-9b and residue(s) on BIR3
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domain of c-IAP1. Caspase-9b/c-IAP1 association enhances the E3 ligase activity of c-IAP1,
which further elevates ubiquitination of RIP1 and NIK. Ubiquitination of RIP1 stimulates
phosphorylation and ubiquitination-mediated degradation of IκB-α, allowing the p65-containing
complexes to translocate into the nucleus and activation of the canonical NF-κB. Via canonical
NF-κB activation, caspase-9b promotes the survival and anchorage-independent growth capacity
of NSCLC cells. In contrast, ubiquitination destabilizes NIK, which prevents the processing of
NF-κB2, nuclear transport of p52-containing complexes and the non-canonical NF-κB activation.
All experiments were repeated at least twice.
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Figure 2.13 Down-regulation of cIAP2 has no effect on NF-κB activation and does not
inhibit the effect of caspase-9b on NF-κB pathway. A549 cells were transfected with control
or c-IAP2 siRNA for 48 hours. (A) Total protein extracts were prepared and subjected to
SDS/PAGE/immunoblotting for cIAP2, NIK, NF-κB2 p100/p52, IκB-α or β-actin. (B)
Cytosolic/nuclear protein extracts were prepared and subjected to SDS-PAGE/immunoblotting
for NF-κB p65, NF-κB2, lamin A/C or α-tubulin. (C) Endogenous RIP1or NIK was
immunoprecipitated (IP) from cell lysates and resolved by SDS-PAGE/ immunoblotting for
ubiquitin, RIP1 or NIK.
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Figure 2.14 Down-regulation of c-IAP1 increases in c-IAP2 level. (A) A549 cells were
transfected with control or c-IAP1 siRNA for 48 hours. Total protein extracts were prepared and
subjected to SDS/PAGE/immunoblotting for cIAP1, c-IAP2 or β-actin. (B) A549 cells were
transfected with random control, mutant caspase-9b control or caspase-9b siRNA for 48 hours.
Total protein extracts were prepared and subjected to SDS/PAGE/immunoblotting for caspase-9,
cIAP1, c-IAP2 or β-actin.
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Figure 2.15 The role of caspase-9b in the NF-κB pathway examined in other cell lines.
Human bronchial epithelial primary cells (HBEpC) (A) or lung cancer H838 cells (B) were
transfected with random control, mutant caspase-9b control or caspase-9b siRNA for 48 hours.
Total protein extracts were prepared and subjected to SDS/PAGE/immunoblotting for NF-κB2
p100/p52, IκB-α, caspase-9, NIK or β-actin. NF-κB2 p52 were undetectable in HBEpC.
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Figure 2.16 NF-κB activation in H838, A549 and HBEpC cells. A549 (mutant K-ras, wildtype p53), H838 (wild-type K-ras, wild-type p53) and HBEpC cells were cultured under the
same and confluency. (A) Total protein extracts were subjected to SDS-PAGE/immunoblotting
for NF-κB2, NIK or β-actin. (B) Cytosolic/ nuclear fractions were prepared and cytosolic/nuclear
protein extracts were subjected to SDS-PAGE/immunoblotting for NF-κB p65, NF-κB2, lamin
A/C or α-tubulin.
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CHAPTER 8 – DISCUSSION:
MECHANISTIC FUNCTIONS OF CASPASE-9B IN THE NF-ΚB PATHWAY

Despite the well-documented function of caspase family in the initiation and execution of
apoptosis, several studies have implicated caspases in the activation of anti-apoptotic NF-κB
pathway. Caspases known to activate NF-κB signaling include caspase-1, -2, -8, -10 (9, 37, 38,
56). The role of caspase-9 in NF-κB activation remains controversial since the CARD domain of
caspase-9 has been validated to enhance NF-κB activity (61) but in another report, caspase-9 has
not been shown to activate NF-κB pathway (9). Particular to caspase-9b isoform, there is not
convincing evidence for its correlation with NF-κB activation and generally, little is known
about mechanistic roles of caspase-9b outside of its only-known function in inhibition of
caspase-9a. Importantly, up-to-date studies regarding the mechanistic functions of caspases in
NF-κB signaling focus mainly on the canonical pathway. Our study emphasized the roles of
caspase-9b in both arms of the NF-κB signaling, the canonical and noncanonical pathway.
Caspase-9b was demonstrated to activate the canonical NF-κB pathway, the only arm of the
NF-κB signaling reported to promote tumor development in NSCLC (2, 47). Consistent with the
literature, activation of the canonical NF-κB was shown to mediate the enhancing effects of
caspase-9b on the survival and anchorage-independent growths of NSCLC cells. To date, the
majority of studies regarding the contribution of NF-κB signaling to tumorigenesis focus on
canonical NF-κB pathway and the roles of non-canonical NF-κB pathway in lung cancer
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development have not been specifically investigated. Caspase-9b regulates both arms of the NFκB pathways in the opposite manner, giving rise to an idea that the non-canonical pathway might
negatively affect tumor-promoting roles of the canonical pathway or activation of the canonical
pathway. Supporting this hypothesis, non-canonical activation has been observed to prevent
canonical activation in different ways (1, 39). There is likely a functional interplay between the
two pathways to fine-tuning the gene transcription activity. Nevertheless, it is unlikely that the
noncanonical pathway is a compensatory redundant mechanism for the canonical pathway due to
the observation that when activation of the noncanonical pathway was favored as a result of
caspase-9b downregulation, there was a significant decrease in the survival and anchorageindependent growth of NSCLC cells. It is plausible that under the suppressed condition of the
canonical arm, the non-canonical arm is activated to maintain a basal level of NF-κB activity but
it is for other biological functions rather than cell survival and growth in an anchorageindependent manner.
NF-κB activation has been implicated in cancer development and resistance to anti-cancer
drugs (30, 52, 66). NF-κB pathway is thereby an attractive target for cancer therapeutic design.
Caspase-9b was observed in this study to enhance the survival and anchorage-independent
growth of NSCLC cells via direct association with c-IAP1 and activation of the canonical NF-κB
pathway. Hence, targeting NF-κB signaling through interfering caspase-9b-c-IAP1 interaction
would be a promising approach to inhibit the canonical NF-κB pathway and further compromise
lung cancer development. An alternative approach to reduce canonical NF-κB activation is
lowering caspase-9b level in NSCLC cells by down-regulating the expression of caspase-9b or
modulating the alternative splicing of caspase-9 pre-mRNA to favor the formation of caspase-9a
instead of caspase-9b. The significance of therapies targeting caspase-9b or caspase-9b-cIAP1
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interaction is the specificity for cancer/tumor cells as cascape-9b is unnoticeably expressed in
non-transformed cells (21). In other words, utilization of caspase-9b-targeting approach is ideal
for cancer-specific treatment. Although NF-κB inhibitors have been shown to be promising for
therapeutic treatment against cancer, there is a serious concern about using NF-κB inhibitors in
cancer therapy: suppressing the NF-κB signaling may impair immunity since NF-κB pathways
play crucial roles in both innate and adaptive immunity. Hence, caspase-9b-targeting approach
for restricting canonical NF-κB activation would not only be cancer-specific but also address the
main problem associated with using NF-κB inhibitors in cancer treatment: therapies preventing
caspase-9b-mediated NF-κB activation would affect the NF-κB signaling only in tumor cells but
not in normal cells and thereby, have a limited effect on the immunity.
c-IAP1 was identified as a key factor mediating the mechanistic and biological roles of
caspase-9b in the NF-κB pathways. Interesting, depletion of c-IAP2, a closely related IAP to cIAP1, was not shown to affect the activating/inhibitory roles of caspase-9b on the NF-κB
pathways (figure 2.13). Also, c-IAP2 did not compensate for the loss of c-IAP1; specifically,
elevated level of c-IAP2 as a consequence of c-IAP1 down-regulation (figure 2.14A) did not
‘rescue’ the blocking effect of cIAP1 down-regulation on caspase-9b-mediated reduction of IκBα and NIK level or ubiquitination of RIP1 and NIK (figure 2.7). Many reports have pointed out
the critical roles of c-IAPs in the NF-κB signaling; however, it has not been well-documented
whether exclusive c-IAP1 or c-IAP2 or both c-IAPs play(s) roles in the NF-κB pathways and in
which circumstances and whether redundant compensatory roles exist between c-IAP1 and cIAP2. With respect to the facilitating functions for caspase-9b in the NF-κB pathways, this study
ruled out the redundant roles between two c-IAPs and highlighted the exclusive roles of c-IAP1
but not c-IAP2.
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The IBM on caspase-9b and and D320 residue in BIR3 domain of c-IAP1 was identified to
be essential for the interaction between caspase-9b and c-IAP1. Interestingly, despite being
reported to be important for caspase-9 binding (16), mutation at this residue has not been shown
to affect c-IAP1 binding to another IBM-containing protein, Smac/DIABLO (54). Three other
mutations in BIR2 or BIR3 of c-IAP1 have also been utilized in this study and all of these
mutations have been reported to disrupted c-IAP1 binding to caspase-9 or Smac/DIABLO (16,
54). However, none of these mutations were observed to decrease c-IAP1 binding to caspase-9b
(figure 2.10). Another interesting finding regarding c-IAP1/caspase-9b interaction is that
caspase-9b does not need to be cleaved to binds to c-IAP1 as caspase-9 (figure 2.9). The
differences in binding mode between c-IAP1/caspase-9b and c-IAP1-/caspase-9 can be explained
by the possibility that truncated caspase-9b has an altered configuration compared to full-size
caspase-9, which still interacts with c-IAP1 at BIR3 domain but at different residues and is no
longer required processing to expose its IBM for binding to c-IAP1.
Caspase-9b binds to c-IAP1 and enhances its E3 ligase activity for canonical NF-κB
activation or noncanonical NF-κB supression. A remaining question is how this interaction with
caspase-9b augments the E3 ligase activity of c-IAP1. Given that the CARD domain on c-IAP1
can autoinhibit its E3 activity by preventing the RING dimerization and blocking the access to
E2 activating enzyme (43), association with caspase-9b might change the conformation of cIAP1 from inactive to active form, which would no longer be affected by CARD-mediated
autoinhibition. This hypothesis could be addressed by further determination of c-IAP1 structure
in the binding configuration with caspase-9b.
Here we have revealed that caspase-9b exhibits opposing functions in the NF-κB pathways in
a NSCLC cell line, A549 (wild-type p53 and mutant Kras genotype). The activating roles of
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caspase-9b in the canonical NF-κB pathway also translated to another NSCLC cell line, H838
(wild-type p53 and wild-type K-ras genotype) and nontransformed bronchial epithelial primary
cell line, HBEpC (figure 2.15). However, caspase-9b was not shown to affect the non-canonical
pathway in either H838 or HBEpC (figure 2.15). This observation could be explained by another
observation that non-canonical activation is undetectable or relatively low in HBEpC and H838
compared to A549 cells (figure 2.16). Also, it is likely that the noncanonical pathway might
negatively impact the canonical activation. In other words, caspase-9b suppresses the
noncanonical pathway to favor the canonical activation and in cases of cells with noncanonical
activation at lower level than the basal level for suppressing the canonical pathway, inhibition of
the noncanonical pathway might be unnecessary.
Based on this study, down-regulation of c-IAP1 resulted in similar outcomes as downregulation of caspase-9b, particularly the effects on NF-κB pathways (figure 2.6), which supports
the idea regarding cooperation between c-IAP1 and caspase-9b in regulation of NF-κB signaling.
Nonetheless, different from caspase-9b, which was demonstrated to promote cell survival, cIAP1 reduction did not alter the viability of NSCLC cells (figure 2.7). Since c-IAP1 depletion
was shown to remarkably increase c-IAP2 level (figure 2.14A), it is likely that c-IAP2 activates
other survival pathways or inhibits cell death pathways in a NF-κB-independent manner to
compensate for the loss of c-IAP1. However, this possibility was ruled out by the observation
that down-regulation of caspase-9b also led to an increase in c-IAP2 level (figure 2.14B).
Therefore, another possible and more likely explanation for the difference between c-IAP1 and
caspase-9b with respects to the effects on cell survival is based on the anti-apoptotic function of
caspase-9b besides its roles in NF-κB signaling. In the absence of c-IAP1 for canonical NF-κB
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activation to maintain cell survival, caspase-9b might help protect cells from undergoing
apoptosis by preventing the activation of caspase-9 and down-stream caspase cascade.
The canonical NF-kB pathway has been shown to be important for the development of Krasinduced lung tumor (2). It is plausible that by activating the canonical NF-kB, caspase-9b might
facilitate Kras-mediated lung tumor formation. Therefore, our future effort will focus on
determining if caspase-9b cooperates with KRAS mutation to drive tumorigenesis in mouse
model. Specifically, adenovirus expressing caspase-9b will be delivered to the mutant KrasG12V
transgenic mice to examine whether expression of caspase-9b augments the enhancing effect of
KRAS mutation on tumoregenesis. If we could validate this hypothesis, targeting caspase-9b
would be an attractive anti-NSCLC approach for patients carrying KRAS mutation.
This study has pointed to the importance of caspase-9b/cIAP1 interaction for tumorigenicity
of NSCLC cells. Hence, identification of compounds that prevent the binding of caspase-9b to
cIAP1 would be a potential approach for development of chemotherapeutic drugs to treat
NSCLC, which is also our future direction besides validating the proposed hypothesis regarding
the cooperation between caspase-9b and KRAS mutation on tumorigenesis. Specifically, we will
perform high throughput screening (HTS) for drug compounds that interferes with caspase-9b/cIAP1 binding. The first step in this process will be identification and optimization of a high
throughput assay that allows specific measurement of caspase-9b/cIAP1 interaction.
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